--12-31 2020 Q3 0000896622 false 0000896622 2020-01-01 2020-09-30 xbrli:shares 0000896622 2020-10-23 iso4217:USD 0000896622 2020-07-01 2020-09-30 0000896622 2019-07-01 2019-09-30 0000896622 2019-01-01 2019-09-30 iso4217:USD xbrli:shares 0000896622 2020-09-30 0000896622 2019-12-31 0000896622 us-gaap:RetainedEarningsMember 2019-06-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000896622 us-gaap:CommonStockMember 2019-06-30 0000896622 us-gaap:TreasuryStockMember 2019-06-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-06-30 0000896622 2019-06-30 0000896622 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000896622 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000896622 us-gaap:RetainedEarningsMember 2019-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000896622 us-gaap:CommonStockMember 2019-09-30 0000896622 us-gaap:TreasuryStockMember 2019-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-09-30 0000896622 2019-09-30 0000896622 us-gaap:RetainedEarningsMember 2020-06-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000896622 us-gaap:CommonStockMember 2020-06-30 0000896622 us-gaap:TreasuryStockMember 2020-06-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000896622 us-gaap:NoncontrollingInterestMember 2020-06-30 0000896622 2020-06-30 0000896622 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000896622 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000896622 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000896622 us-gaap:RetainedEarningsMember 2020-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000896622 us-gaap:CommonStockMember 2020-09-30 0000896622 us-gaap:TreasuryStockMember 2020-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2020-09-30 0000896622 us-gaap:RetainedEarningsMember 2018-12-31 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000896622 us-gaap:CommonStockMember 2018-12-31 0000896622 us-gaap:TreasuryStockMember 2018-12-31 0000896622 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000896622 us-gaap:NoncontrollingInterestMember 2018-12-31 0000896622 2018-12-31 0000896622 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000896622 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000896622 us-gaap:RetainedEarningsMember 2019-12-31 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000896622 us-gaap:CommonStockMember 2019-12-31 0000896622 us-gaap:TreasuryStockMember 2019-12-31 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000896622 us-gaap:NoncontrollingInterestMember 2019-12-31 0000896622 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0000896622 us-gaap:RetainedEarningsMember us-gaap:AccountingStandardsUpdate201613Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000896622 us-gaap:AccountingStandardsUpdate201613Member srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000896622 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000896622 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000896622 country:AR 2020-04-01 2020-06-30 xbrli:pure 0000896622 srt:MaximumMember us-gaap:SalesRevenueNetMember country:AR us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000896622 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201613Member 2020-01-01 0000896622 atr:BeautyAndHomeMember srt:EuropeMember 2020-07-01 2020-09-30 0000896622 atr:BeautyAndHomeMember srt:NorthAmericaMember 2020-07-01 2020-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2020-07-01 2020-09-30 0000896622 atr:BeautyAndHomeMember srt:AsiaMember 2020-07-01 2020-09-30 0000896622 atr:BeautyAndHomeMember 2020-07-01 2020-09-30 0000896622 atr:PharmaMember srt:EuropeMember 2020-07-01 2020-09-30 0000896622 atr:PharmaMember srt:NorthAmericaMember 2020-07-01 2020-09-30 0000896622 atr:PharmaMember srt:LatinAmericaMember 2020-07-01 2020-09-30 0000896622 atr:PharmaMember srt:AsiaMember 2020-07-01 2020-09-30 0000896622 atr:PharmaMember 2020-07-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:EuropeMember 2020-07-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:NorthAmericaMember 2020-07-01 2020-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2020-07-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:AsiaMember 2020-07-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember 2020-07-01 2020-09-30 0000896622 srt:EuropeMember 2020-07-01 2020-09-30 0000896622 srt:NorthAmericaMember 2020-07-01 2020-09-30 0000896622 srt:LatinAmericaMember 2020-07-01 2020-09-30 0000896622 srt:AsiaMember 2020-07-01 2020-09-30 0000896622 atr:BeautyAndHomeMember srt:EuropeMember 2019-07-01 2019-09-30 0000896622 atr:BeautyAndHomeMember srt:NorthAmericaMember 2019-07-01 2019-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 atr:BeautyAndHomeMember srt:AsiaMember 2019-07-01 2019-09-30 0000896622 atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember srt:EuropeMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember srt:NorthAmericaMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember srt:LatinAmericaMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember srt:AsiaMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember 2019-07-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:EuropeMember 2019-07-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:NorthAmericaMember 2019-07-01 2019-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:AsiaMember 2019-07-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 srt:EuropeMember 2019-07-01 2019-09-30 0000896622 srt:NorthAmericaMember 2019-07-01 2019-09-30 0000896622 srt:LatinAmericaMember 2019-07-01 2019-09-30 0000896622 srt:AsiaMember 2019-07-01 2019-09-30 0000896622 atr:BeautyAndHomeMember srt:EuropeMember 2020-01-01 2020-09-30 0000896622 atr:BeautyAndHomeMember srt:NorthAmericaMember 2020-01-01 2020-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2020-01-01 2020-09-30 0000896622 atr:BeautyAndHomeMember srt:AsiaMember 2020-01-01 2020-09-30 0000896622 atr:BeautyAndHomeMember 2020-01-01 2020-09-30 0000896622 atr:PharmaMember srt:EuropeMember 2020-01-01 2020-09-30 0000896622 atr:PharmaMember srt:NorthAmericaMember 2020-01-01 2020-09-30 0000896622 atr:PharmaMember srt:LatinAmericaMember 2020-01-01 2020-09-30 0000896622 atr:PharmaMember srt:AsiaMember 2020-01-01 2020-09-30 0000896622 atr:PharmaMember 2020-01-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:EuropeMember 2020-01-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:NorthAmericaMember 2020-01-01 2020-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2020-01-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:AsiaMember 2020-01-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember 2020-01-01 2020-09-30 0000896622 srt:EuropeMember 2020-01-01 2020-09-30 0000896622 srt:NorthAmericaMember 2020-01-01 2020-09-30 0000896622 srt:LatinAmericaMember 2020-01-01 2020-09-30 0000896622 srt:AsiaMember 2020-01-01 2020-09-30 0000896622 atr:BeautyAndHomeMember srt:EuropeMember 2019-01-01 2019-09-30 0000896622 atr:BeautyAndHomeMember srt:NorthAmericaMember 2019-01-01 2019-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 atr:BeautyAndHomeMember srt:AsiaMember 2019-01-01 2019-09-30 0000896622 atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember srt:EuropeMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember srt:NorthAmericaMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember srt:LatinAmericaMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember srt:AsiaMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember 2019-01-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:EuropeMember 2019-01-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:NorthAmericaMember 2019-01-01 2019-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember srt:AsiaMember 2019-01-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 srt:EuropeMember 2019-01-01 2019-09-30 0000896622 srt:NorthAmericaMember 2019-01-01 2019-09-30 0000896622 srt:LatinAmericaMember 2019-01-01 2019-09-30 0000896622 srt:AsiaMember 2019-01-01 2019-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:OperatingSegmentsMember 2019-12-31 0000896622 atr:PharmaMember us-gaap:OperatingSegmentsMember 2019-12-31 0000896622 us-gaap:FoodAndBeverageMember us-gaap:OperatingSegmentsMember 2019-12-31 0000896622 us-gaap:CorporateNonSegmentMember 2019-12-31 0000896622 atr:BeautyAndHomeMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000896622 atr:PharmaMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000896622 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:OperatingSegmentsMember 2020-09-30 0000896622 atr:PharmaMember us-gaap:OperatingSegmentsMember 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:OperatingSegmentsMember 2020-09-30 0000896622 us-gaap:CorporateNonSegmentMember 2020-09-30 0000896622 us-gaap:PatentsMember srt:WeightedAverageMember 2020-01-01 2020-09-30 0000896622 us-gaap:PatentsMember 2020-09-30 0000896622 us-gaap:PatentsMember 2019-12-31 0000896622 us-gaap:PatentedTechnologyMember srt:WeightedAverageMember 2020-01-01 2020-09-30 0000896622 us-gaap:PatentedTechnologyMember 2020-09-30 0000896622 us-gaap:PatentedTechnologyMember 2019-12-31 0000896622 us-gaap:CustomerRelationshipsMember srt:WeightedAverageMember 2020-01-01 2020-09-30 0000896622 us-gaap:CustomerRelationshipsMember 2020-09-30 0000896622 us-gaap:CustomerRelationshipsMember 2019-12-31 0000896622 us-gaap:TrademarksAndTradeNamesMember srt:WeightedAverageMember 2020-01-01 2020-09-30 0000896622 us-gaap:TrademarksAndTradeNamesMember 2020-09-30 0000896622 us-gaap:TrademarksAndTradeNamesMember 2019-12-31 0000896622 srt:WeightedAverageMember atr:LicensingAgreementsAndOtherProductMember 2020-01-01 2020-09-30 0000896622 atr:LicensingAgreementsAndOtherProductMember 2020-09-30 0000896622 atr:LicensingAgreementsAndOtherProductMember 2019-12-31 0000896622 srt:WeightedAverageMember 2020-01-01 2020-09-30 0000896622 us-gaap:NotesPayableToBanksMember 2020-01-01 2020-09-30 0000896622 us-gaap:NotesPayableToBanksMember 2020-09-30 0000896622 us-gaap:NotesPayableToBanksMember 2019-12-31 0000896622 us-gaap:LineOfCreditMember 2020-01-01 2020-09-30 0000896622 us-gaap:LineOfCreditMember 2020-09-30 0000896622 us-gaap:LineOfCreditMember 2019-12-31 0000896622 srt:MinimumMember us-gaap:BankOverdraftsMember 2020-01-01 2020-09-30 0000896622 srt:MaximumMember us-gaap:BankOverdraftsMember 2020-01-01 2020-09-30 0000896622 us-gaap:BankOverdraftsMember 2020-09-30 0000896622 us-gaap:BankOverdraftsMember 2019-12-31 atr:tranche 0000896622 atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member 2020-01-01 2020-09-30 0000896622 atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member 2020-09-30 iso4217:EUR 0000896622 atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member 2019-12-31 0000896622 us-gaap:NotesPayableOtherPayablesMember srt:MinimumMember 2020-09-30 0000896622 us-gaap:NotesPayableOtherPayablesMember srt:MaximumMember 2020-09-30 0000896622 us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0000896622 atr:SeniorUnsecuredNotes3.2PercentDue2022Member 2020-09-30 0000896622 us-gaap:NotesPayableToBanksMember 2020-09-30 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2023Member 2020-09-30 0000896622 atr:SeniorUnsecuredNotes0.98DueIn2023Member 2020-09-30 0000896622 atr:SeniorUnsecuredNotes3.4PercentDue2024Member 2020-09-30 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2024Member 2020-09-30 0000896622 atr:SeniorUnsecuredNotes1.17DueIn2024Member 2020-09-30 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2025Member 2020-09-30 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2026Member 2020-09-30 0000896622 us-gaap:NotesPayableOtherPayablesMember srt:MinimumMember 2019-12-31 0000896622 us-gaap:NotesPayableOtherPayablesMember srt:MaximumMember 2019-12-31 0000896622 us-gaap:NotesPayableOtherPayablesMember 2019-12-31 0000896622 atr:SeniorUnsecuredNotes3.2PercentDue2022Member 2019-12-31 0000896622 us-gaap:NotesPayableToBanksMember 2019-12-31 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2023Member 2019-12-31 0000896622 atr:SeniorUnsecuredNotes0.98DueIn2023Member 2019-12-31 0000896622 atr:SeniorUnsecuredNotes3.4PercentDue2024Member 2019-12-31 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2024Member 2019-12-31 0000896622 atr:SeniorUnsecuredNotes1.17DueIn2024Member 2019-12-31 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2025Member 2019-12-31 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2026Member 2019-12-31 0000896622 srt:MaximumMember 2020-09-30 0000896622 srt:MinimumMember 2020-09-30 0000896622 country:US 2020-07-01 2020-09-30 0000896622 country:US 2019-07-01 2019-09-30 0000896622 us-gaap:ForeignPlanMember 2020-07-01 2020-09-30 0000896622 us-gaap:ForeignPlanMember 2019-07-01 2019-09-30 0000896622 country:US 2020-01-01 2020-09-30 0000896622 country:US 2019-01-01 2019-09-30 0000896622 us-gaap:ForeignPlanMember 2020-01-01 2020-09-30 0000896622 us-gaap:ForeignPlanMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:NotesPayableToBanksMember 2017-01-01 2017-12-31 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember 2017-12-31 0000896622 us-gaap:NotesPayableToBanksMember 2017-12-31 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-09-30 0000896622 us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2020-09-30 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember 2020-09-30 0000896622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-09-30 0000896622 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2020-09-30 0000896622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000896622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000896622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-12-31 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-09-30 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-12-31 0000896622 us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000896622 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-09-30 0000896622 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000896622 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-12-31 0000896622 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000896622 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000896622 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-12-31 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2020-09-30 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-12-31 0000896622 us-gaap:InterestExpenseMember us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2020-07-01 2020-09-30 0000896622 us-gaap:InterestExpenseMember us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2019-07-01 2019-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000896622 us-gaap:CashFlowHedgingMember 2020-07-01 2020-09-30 0000896622 us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000896622 us-gaap:InterestExpenseMember us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2020-01-01 2020-09-30 0000896622 us-gaap:InterestExpenseMember us-gaap:CashFlowHedgingMember us-gaap:InterestRateSwapMember 2019-01-01 2019-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000896622 us-gaap:CashFlowHedgingMember 2020-01-01 2020-09-30 0000896622 us-gaap:CashFlowHedgingMember 2019-01-01 2019-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2020-07-01 2020-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000896622 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000896622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000896622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000896622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-09-30 0000896622 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000896622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000896622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-12-31 0000896622 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-12-31 0000896622 atr:FusionPackagingMember 2020-09-30 0000896622 atr:NobleMember 2020-09-30 0000896622 atr:GatewayAnalyticalMember 2020-07-01 2020-09-30 0000896622 atr:NobleMember 2019-12-31 0000896622 atr:GatewayAnalyticalMember 2019-12-31 0000896622 us-gaap:IndemnificationGuaranteeMember 2019-12-31 0000896622 us-gaap:IndemnificationGuaranteeMember 2020-09-30 0000896622 us-gaap:FireMember country:FR 2020-09-30 0000896622 country:BR 2017-03-31 0000896622 country:BR 2019-01-01 2019-12-31 0000896622 country:BR 2020-01-01 2020-09-30 0000896622 country:BR 2020-09-30 0000896622 country:BR us-gaap:ReductionInTaxesMember 2019-03-31 0000896622 us-gaap:CostOfSalesMember country:BR us-gaap:ReductionInTaxesMember 2019-03-31 0000896622 us-gaap:InterestIncomeMember country:BR us-gaap:ReductionInTaxesMember 2019-03-31 0000896622 country:BR us-gaap:ReductionInTaxesMember 2020-06-30 0000896622 us-gaap:CostOfSalesMember country:BR us-gaap:ReductionInTaxesMember 2020-06-30 0000896622 srt:MinimumMember country:BR us-gaap:ReductionInTaxesMember 2020-09-30 0000896622 srt:MaximumMember country:BR us-gaap:ReductionInTaxesMember 2020-09-30 0000896622 atr:TaxAssessmentMember country:BR 2019-12-31 0000896622 atr:TaxAssessmentInterestMember country:BR 2019-12-31 0000896622 atr:TaxAssessmentPenalitesMember country:BR 2019-12-31 0000896622 atr:TaxAssessmentMember country:BR 2020-09-30 0000896622 atr:StockRepurchaseProgramApril182019Member 2019-04-18 0000896622 atr:RestrictedStockUnitsTimeBasedMember 2020-01-01 2020-09-30 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2020-01-01 2020-09-30 0000896622 atr:DirectorStockOptionPlansMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2019-01-01 2019-09-30 0000896622 atr:RestrictedStockUnitsTimeBasedMember 2019-12-31 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2019-12-31 0000896622 atr:RestrictedStockUnitsTimeBasedMember 2020-09-30 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2020-09-30 0000896622 atr:DirectorStockOptionPlansMember atr:RestrictedStockUnitsTimeBasedMember 2020-01-01 2020-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:SellingResearchAndDevelopmentAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:SellingResearchAndDevelopmentAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000896622 atr:StockAwardPlansMember us-gaap:EmployeeStockOptionMember 2019-12-31 0000896622 atr:DirectorStockOptionPlansMember us-gaap:EmployeeStockOptionMember 2019-12-31 0000896622 atr:StockAwardPlansMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000896622 atr:DirectorStockOptionPlansMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000896622 atr:StockAwardPlansMember us-gaap:EmployeeStockOptionMember 2020-09-30 0000896622 atr:DirectorStockOptionPlansMember us-gaap:EmployeeStockOptionMember 2020-09-30 0000896622 atr:StockAwardPlansMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000896622 atr:DirectorStockOptionPlansMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2020-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 atr:segment 0000896622 atr:BeautyAndHomeMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000896622 atr:PharmaMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000896622 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000896622 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000896622 atr:BeautyAndHomeMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000896622 atr:PharmaMember us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000896622 atr:PharmaMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000896622 us-gaap:FoodAndBeverageMember us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2020-07-01 2020-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2020-01-01 2020-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000896622 us-gaap:CorporateAndOtherMember 2020-07-01 2020-09-30 0000896622 us-gaap:CorporateAndOtherMember 2019-07-01 2019-09-30 0000896622 us-gaap:CorporateAndOtherMember 2020-01-01 2020-09-30 0000896622 us-gaap:CorporateAndOtherMember 2019-01-01 2019-09-30 0000896622 atr:FusionPackagingMember 2020-04-01 0000896622 atr:FusionPackagingMember 2020-04-01 2020-04-01 0000896622 atr:FusionPackagingMember 2020-07-01 2020-09-30 0000896622 atr:FusionPackagingMember 2020-01-01 2020-09-30 0000896622 atr:NobleMember 2019-10-31 0000896622 atr:NobleMember 2019-10-31 2019-10-31 0000896622 atr:NobleMember 2020-01-01 2020-03-31 0000896622 atr:NanopharmMember 2019-06-05 2019-06-05 0000896622 atr:NanopharmMember 2019-06-05 0000896622 atr:GatewayAnalyticalMember 2019-05-31 2019-05-31 0000896622 atr:GatewayAnalyticalMember 2019-05-31 0000896622 atr:GatewayAnalyticalMember 2020-04-01 2020-06-30 0000896622 atr:Acquisitions2019Member 2019-12-31 0000896622 atr:FusionPackagingMember 2019-12-31 0000896622 atr:Acquisitions2019Member 2020-09-30 0000896622 us-gaap:PatentedTechnologyMember atr:FusionPackagingMember 2020-01-01 2020-09-30 0000896622 us-gaap:PatentedTechnologyMember atr:FusionPackagingMember 2020-09-30 0000896622 us-gaap:PatentedTechnologyMember atr:Acquisitions2019Member 2019-01-01 2019-12-31 0000896622 us-gaap:PatentedTechnologyMember atr:Acquisitions2019Member 2019-12-31 0000896622 us-gaap:CustomerRelationshipsMember atr:FusionPackagingMember 2020-01-01 2020-09-30 0000896622 us-gaap:CustomerRelationshipsMember atr:FusionPackagingMember 2020-09-30 0000896622 us-gaap:CustomerRelationshipsMember atr:Acquisitions2019Member 2019-01-01 2019-12-31 0000896622 us-gaap:CustomerRelationshipsMember atr:Acquisitions2019Member 2019-12-31 0000896622 us-gaap:TrademarksAndTradeNamesMember atr:FusionPackagingMember 2020-01-01 2020-09-30 0000896622 us-gaap:TrademarksAndTradeNamesMember atr:FusionPackagingMember 2020-09-30 0000896622 us-gaap:TrademarksAndTradeNamesMember atr:Acquisitions2019Member 2019-01-01 2019-12-31 0000896622 us-gaap:TrademarksAndTradeNamesMember atr:Acquisitions2019Member 2019-12-31 0000896622 atr:FusionPackagingMember atr:LicensingAgreementsAndOtherProductMember 2020-01-01 2020-09-30 0000896622 atr:FusionPackagingMember atr:LicensingAgreementsAndOtherProductMember 2020-09-30 0000896622 atr:Acquisitions2019Member atr:LicensingAgreementsAndOtherProductMember 2019-01-01 2019-12-31 0000896622 atr:Acquisitions2019Member atr:LicensingAgreementsAndOtherProductMember 2019-12-31 0000896622 atr:FusionPackagingMember 2019-07-01 2019-09-30 0000896622 atr:FusionPackagingMember 2019-01-01 2019-09-30 0000896622 atr:BapcoClosuresHoldingLimitedMember 2019-08-02 0000896622 atr:BapcoClosuresHoldingLimitedMember 2019-08-02 2019-08-02 0000896622 atr:BapcoClosuresHoldingLimitedMember atr:BapcoClosuresHoldingLimitedMember 2018-12-31 0000896622 atr:BtyMember 2020-09-30 0000896622 atr:BtyMember 2019-12-31 0000896622 atr:SonmolMember 2020-09-30 0000896622 atr:SonmolMember 2019-12-31 0000896622 atr:KaliCareMember 2020-09-30 0000896622 atr:KaliCareMember 2019-12-31 0000896622 atr:DesotecGmbhMember 2020-09-30 0000896622 atr:DesotecGmbhMember 2019-12-31 0000896622 atr:SonmolMember 2020-04-01 2020-04-01 0000896622 atr:SonmolMember 2020-04-01 0000896622 atr:BtyMember 2020-01-01 0000896622 atr:BtyMember us-gaap:CallOptionMember srt:MinimumMember 2020-01-01 0000896622 srt:MaximumMember atr:BtyMember us-gaap:CallOptionMember 2020-01-01 0000896622 atr:BtyMember 2020-01-01 2020-01-01 0000896622 atr:KaliCareMember 2017-01-01 2017-12-31 0000896622 atr:KaliCareMember 2017-12-31 0000896622 atr:DesotecGmbhMember 2009-01-01 2009-12-31 0000896622 atr:DesotecGmbhMember 2009-12-31 0000896622 atr:LoopAndPurecycleMember us-gaap:PreferredStockMember 2019-08-01 2019-08-31 atr:investment 0000896622 atr:LoopAndPurecycleMember us-gaap:PreferredStockMember 2019-08-31 0000896622 atr:LoopAndPurecycleMember us-gaap:PreferredStockMember 2020-07-01 2020-09-30 0000896622 atr:BusinessTransformationPlanMember 2020-07-01 2020-09-30 0000896622 atr:BusinessTransformationPlanMember 2020-01-01 2020-09-30 0000896622 atr:BusinessTransformationPlanMember 2019-07-01 2019-09-30 0000896622 atr:BusinessTransformationPlanMember 2019-01-01 2019-09-30 0000896622 atr:BusinessTransformationPlanMember 2020-09-30 0000896622 atr:BusinessTransformationPlanMember 2018-01-01 2020-09-30 0000896622 us-gaap:EmployeeSeveranceMember 2019-12-31 0000896622 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0000896622 us-gaap:EmployeeSeveranceMember 2020-09-30 0000896622 atr:OtherRestructuringCostsMember 2019-12-31 0000896622 atr:OtherRestructuringCostsMember 2020-01-01 2020-09-30 0000896622 atr:OtherRestructuringCostsMember 2020-09-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
​
FORM 10-Q
​
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
​
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020
​
OR
​
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
​
FOR THE TRANSITION PERIOD FROM TO

COMMISSION FILE NUMBER 1-11846
AptarGroup, Inc.​

Delaware | ​ | 36-3853103
(State of Incorporation) | ​ | (I.R.S. Employer Identification No.)

​
265 EXCHANGE DRIVE, SUITE 100, CRYSTAL LAKE, IL 60014
​
815-477-0424
​
Securities registered pursuant to Section 12(b) of the Act:​

Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common Stock, $.01 par value | ATR | New York Stock Exchange

​
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻
​
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻
​
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
​

Large accelerated filer | ☑ | Accelerated filer | ☐ | Non-accelerated filer | ☐ | Smaller reporting company | ☐ | Emerging growth company | ☐

​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻
​
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ
​
The number of shares outstanding of common stock, as of October 23, 2020, was 64,722,498 shares.
​​

​

Table of Contents

​
AptarGroup, Inc.
​
Form 10-Q
​
Quarter Ended September 30, 2020
​
INDEX​

​

Part I. | FINANCIAL INFORMATION | ​
​ | ​ | ​
Item 1. | Financial Statements (Unaudited) | ​
​ | ​ | ​
​ | Condensed Consolidated Statements of Income – Three and Nine Months Ended September 30, 2020 and 2019 | 1
​ | ​ | ​
​ | Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2020 and 2019 | 2
​ | ​ | ​
​ | Condensed Consolidated Balance Sheets – September 30, 2020 and December 31, 2019 | 3
​ | ​ | ​
​ | Condensed Consolidated Statements of Changes in Equity – Three and Nine Months Ended September 30, 2020 and 2019 | 5
​ | ​ | ​
​ | Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2020 and 2019 | 7
​ | ​ | ​
​ | Notes to Condensed Consolidated Financial Statements | 9
​ | ​ | ​
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 32
​ | ​ | ​
Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 49
​ | ​ | ​
Item 4. | Controls and Procedures | 49
​ | ​ | ​
Part II. | OTHER INFORMATION | ​
​ | ​ | ​
Item 1A. | Risk Factors | 50
​ | ​ | ​
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 50
​ | ​ | ​
Item 6. | Exhibits | 51
​ | ​ | ​
​ | Signature | 52

i

Table of Contents
PART I – FINANCIAL INFORMATION
​
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
​
AptarGroup, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
​

In thousands, except per share amounts
​ | ​ |  | ​ |  | ​ |  | ​
​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
​ | ​ |  | ​ |  | ​ |  | ​
Net Sales | $ | 759,153 |  |  | $ | 701,278 |  |  | $ | 2,180,011 |  |  | $ | 2,188,399 |
Operating Expenses: | ​ |  | ​ |  | ​ |  | ​
Cost of sales (exclusive of depreciation and amortization shown below) | 479,672 |  |  | 444,237 |  |  | 1,372,630 |  |  | 1,382,810 |
Selling, research & development and administrative | 121,850 |  |  | 111,559 |  |  | 371,407 |  |  | 346,526 |
Depreciation and amortization | 55,179 |  |  | 49,218 |  |  | 162,414 |  |  | 144,574 |
Restructuring initiatives | 3,415 |  |  | 6,019 |  |  | 15,585 |  |  | 17,286 |
​ | 660,116 |  |  | 611,033 |  |  | 1,922,036 |  |  | 1,891,196 |
Operating Income | 99,037 |  |  | 90,245 |  |  | 257,975 |  |  | 297,203 |
​ | ​ |  | ​ |  | ​ |  | ​
Other (Expense) Income: | ​ |  | ​ |  | ​ |  | ​
Interest expense | (8,851) |  |  | (8,898) |  |  | (25,973) |  |  | (26,868) |
Interest income | 249 |  |  | 957 |  |  | 599 |  |  | 3,738 |
Equity in results of affiliates | (256) |  |  | 238 |  |  | (1,383) |  |  | 152 |
Miscellaneous, net | (1,040) |  |  | (269) |  |  | (3,375) |  |  | 148 |
​ | (9,898) |  |  | (7,972) |  |  | (30,132) |  |  | (22,830) |
​ | ​ |  | ​ |  | ​ |  | ​
Income before Income Taxes | 89,139 |  |  | 82,273 |  |  | 227,843 |  |  | 274,373 |
​ | ​ |  | ​ |  | ​ |  | ​
Provision for Income Taxes | 25,404 |  |  | 25,504 |  |  | 66,998 |  |  | 80,684 |
​ | ​ |  | ​ |  | ​ |  | ​
Net Income | $ | 63,735 |  |  | $ | 56,769 |  |  | $ | 160,845 |  |  | $ | 193,689 |
​ | ​ |  | ​ |  | ​ |  | ​
Net Income Attributable to Noncontrolling Interests | $ | (19) |  |  | $ | (19) |  |  | $ | (37) |  |  | $ | (20) |
​ | ​ |  | ​ |  | ​ |  | ​
Net Income Attributable to AptarGroup, Inc. | $ | 63,716 |  |  | $ | 56,750 |  |  | $ | 160,808 |  |  | $ | 193,669 |
​ | ​ |  | ​ |  | ​ |  | ​
Net Income Attributable to AptarGroup, Inc. per Common Share: | ​ |  | ​ |  | ​ |  | ​
Basic | $ | 0.99 |  |  | $ | 0.89 |  |  | $ | 2.50 |  |  | $ | 3.05 |
Diluted | $ | 0.95 |  |  | $ | 0.85 |  |  | $ | 2.42 |  |  | $ | 2.93 |
​ | ​ |  | ​ |  | ​ |  | ​
Average Number of Shares Outstanding: | ​ |  | ​ |  | ​ |  | ​
Basic | 64,562 |  |  | 64,010 |  |  | 64,278 |  |  | 63,485 |
Diluted | 66,922 |  |  | 66,702 |  |  | 66,483 |  |  | 66,163 |
​ | ​ |  | ​ |  | ​ |  | ​
Dividends per Common Share | $ | 0.36 |  |  | $ | 0.36 |  |  | $ | 1.08 |  |  | $ | 1.06 |

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.​
1

Table of Contents
​AptarGroup, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
​

In thousands | ​ |  | ​ |  | ​ |  | ​
​ | ​ |  | ​ |  | ​ |  | ​
​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
​ | ​ |  | ​ |  | ​ |  | ​
Net Income | $ | 63,735 |  |  | $ | 56,769 |  |  | $ | 160,845 |  |  | $ | 193,689 |
Other Comprehensive Income (Loss): | ​ |  | ​ |  | ​ |  | ​
Foreign currency translation adjustments | 42,425 |  |  | (42,540) |  |  | 19,292 |  |  | (42,737) |
Changes in derivative (losses) gains, net of tax | (147) |  |  | 279 |  |  | 603 |  |  | (593) |
Defined benefit pension plan, net of tax | ​ |  | ​ |  | ​ |  | ​
Amortization of prior service cost included in net income, net of tax | 73 |  |  | 82 |  |  | 216 |  |  | 249 |
Amortization of net loss included in net income, net of tax | 1,490 |  |  | 631 |  |  | 4,423 |  |  | 1,901 |
Total defined benefit pension plan, net of tax | 1,563 |  |  | 713 |  |  | 4,639 |  |  | 2,150 |
Total other comprehensive income (loss) | 43,841 |  |  | (41,548) |  |  | 24,534 |  |  | (41,180) |
Comprehensive Income | 107,576 |  |  | 15,221 |  |  | 185,379 |  |  | 152,509 |
Comprehensive Income Attributable to Noncontrolling Interests | (28) |  |  | (7) |  |  | (47) |  |  | (8) |
Comprehensive Income Attributable to AptarGroup, Inc. | $ | 107,548 |  |  | $ | 15,214 |  |  | $ | 185,332 |  |  | $ | 152,501 |

​
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.​
2

Table of Contents
AptarGroup, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
​

In thousands | ​ |  | ​
​ | ​ |  | ​
​ | September 30, 2020 |  | December 31, 2019
Assets | ​ |  | ​
Current Assets: | ​ |  | ​
Cash and equivalents | $ | 226,546 |  |  | $ | 241,970 |
Accounts and notes receivable, less current expected credit loss ("CECL") of $7,440 in 2020 and $3,626 in 2019 | 593,418 |  |  | 558,428 |
Inventories | 375,177 |  |  | 375,795 |
Prepaid and other | 132,055 |  |  | 115,048 |
​ | 1,327,196 |  |  | 1,291,241 |
Property, Plant and Equipment: | ​ |  | ​
Buildings and improvements | 551,164 |  |  | 504,328 |
Machinery and equipment | 2,679,171 |  |  | 2,521,737 |
​ | 3,230,335 |  |  | 3,026,065 |
Less: Accumulated depreciation | (2,117,684) |  |  | (1,963,520) |
​ | 1,112,651 |  |  | 1,062,545 |
Land | 27,248 |  |  | 25,133 |
​ | 1,139,899 |  |  | 1,087,678 |
Other Assets: | ​ |  | ​
Investments in equity securities | 46,995 |  |  | 8,396 |
Goodwill | 878,015 |  |  | 763,461 |
Intangible assets, net | 347,695 |  |  | 291,084 |
Operating lease right-of-use assets | 72,269 |  |  | 72,377 |
Miscellaneous | 49,680 |  |  | 47,882 |
​ | 1,394,654 |  |  | 1,183,200 |
Total Assets | $ | 3,861,749 |  |  | $ | 3,562,119 |

​
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
3

Table of Contents
AptarGroup, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
​

In thousands, except share and per share amounts | ​ |  | ​
​ | ​ |  | ​
​ | September 30, 2020 |  | December 31, 2019
Liabilities and Stockholders’ Equity | ​ |  | ​
Current Liabilities: | ​ |  | ​
Notes payable, revolving credit facility and overdrafts | $ | 95,200 |  |  | $ | 44,259 |
Current maturities of long-term obligations, net of unamortized debt issuance costs | 66,056 |  |  | 65,988 |
Accounts payable, accrued and other liabilities | 625,865 |  |  | 573,028 |
​ | 787,121 |  |  | 683,275 |
Long-Term Obligations, net of unamortized debt issuance costs | 1,039,935 |  |  | 1,085,453 |
Deferred Liabilities and Other: | ​ |  | ​
Deferred income taxes | 40,120 |  |  | 41,388 |
Retirement and deferred compensation plans | 116,886 |  |  | 101,225 |
Operating lease liabilities | 54,899 |  |  | 55,276 |
Deferred and other non-current liabilities | 62,833 |  |  | 23,250 |
Commitments and contingencies | — |  |  | — |
​ | 274,738 |  |  | 221,139 |
Stockholders’ Equity: | ​ |  | ​
AptarGroup, Inc. stockholders’ equity | ​ |  | ​
Common stock, $.01 par value, 199 million shares authorized, 69.3 and 68.6 million shares issued as of September 30, 2020 and December 31, 2019, respectively | 693 |  |  | 686 |
Capital in excess of par value | 827,273 |  |  | 770,596 |
Retained earnings | 1,613,891 |  |  | 1,523,820 |
Accumulated other comprehensive loss | (317,424) |  |  | (341,948) |
Less: Treasury stock at cost, 4.6 and 4.8 million shares as of September 30, 2020 and December 31, 2019, respectively | (364,861) |  |  | (381,238) |
Total AptarGroup, Inc. Stockholders’ Equity | 1,759,572 |  |  | 1,571,916 |
Noncontrolling interests in subsidiaries | 383 |  |  | 336 |
Total Stockholders’ Equity | 1,759,955 |  |  | 1,572,252 |
Total Liabilities and Stockholders’ Equity | $ | 3,861,749 |  |  | $ | 3,562,119 |

​
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
​
​
4

Table of Contents
AptarGroup, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(Unaudited)
​

In thousands | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Three Months Ended | AptarGroup, Inc. Stockholders’ Equity |  | ​ |  | ​
September 30, 2020 and 2019 | Retained Earnings |  | Accumulated Other Comprehensive (Loss) Income |  | Common Stock Par Value |  | Treasury Stock |  | Capital in Excess of Par Value |  | Non- Controlling Interest |  | Total Equity
​ |  |  |  |  |  |
Balance - June 30, 2019 | $ | 1,464,607 |  |  | $ | (310,136) |  |  | $ | 683 |  |  | $ | (317,380) |  |  | $ | 743,332 |  |  | $ | 316 |  |  | $ | 1,581,422 |
Net income | 56,750 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 19 |  |  | 56,769 |
Foreign currency translation adjustments | — |  |  | (42,528) |  |  | — |  |  | — |  |  | — |  |  | (12) |  |  | (42,540) |
Changes in unrecognized pension gains (losses) and related amortization, net of tax | — |  |  | 713 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 713 |
Changes in derivative gains (losses), net of tax | — |  |  | 279 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 279 |
Stock awards and option exercises | — |  |  | — |  |  | 2 |  |  | 2,512 |  |  | 13,656 |  |  | — |  |  | 16,170 |
Cash dividends declared on common stock | (23,057) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (23,057) |
Treasury stock purchased | — |  |  | — |  |  | — |  |  | (35,777) |  |  | — |  |  | — |  |  | (35,777) |
Balance - September 30, 2019 | $ | 1,498,300 |  |  | $ | (351,672) |  |  | $ | 685 |  |  | $ | (350,645) |  |  | $ | 756,988 |  |  | $ | 323 |  |  | $ | 1,553,979 |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Balance - June 30, 2020 | $ | 1,573,392 |  |  | $ | (361,256) |  |  | $ | 690 |  |  | $ | (370,706) |  |  | $ | 803,511 |  |  | $ | 355 |  |  | $ | 1,645,986 |
Net income | 63,716 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 19 |  |  | 63,735 |
Foreign currency translation adjustments | — |  |  | 42,416 |  |  | — |  |  | — |  |  | — |  |  | 9 |  |  | 42,425 |
Changes in unrecognized pension gains (losses) and related amortization, net of tax | — |  |  | 1,563 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,563 |
Changes in derivative gains (losses), net of tax | — |  |  | (147) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (147) |
Stock awards and option exercises | — |  |  | — |  |  | 3 |  |  | 5,845 |  |  | 23,762 |  |  | — |  |  | 29,610 |
Cash dividends declared on common stock | (23,217) |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (23,217) |
Balance - September 30, 2020 | $ | 1,613,891 |  |  | $ | (317,424) |  |  | $ | 693 |  |  | $ | (364,861) |  |  | $ | 827,273 |  |  | $ | 383 |  |  | $ | 1,759,955 |

5

Table of Contents

In thousands | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Nine Months Ended | AptarGroup, Inc. Stockholders’ Equity |  | ​ |  | ​
September 30, 2020 and 2019 | Retained Earnings |  | Accumulated Other Comprehensive (Loss) Income |  | Common Stock Par Value |  | Treasury Stock |  | Capital in Excess of Par Value |  | Non- Controlling Interest |  | Total Equity
​ |  |  |  |  |  |
Balance - December 31, 2018 | $ | 1,371,826 |  |  | $ | (310,504) |  |  | $ | 673 |  |  | $ | (318,208) |  |  | $ | 678,769 |  |  | $ | 315 |  |  | $ | 1,422,871 |
Net income | 193,669 |  |  | — |  | — |  | — |  | — |  | 20 |  |  | 193,689 |
Foreign currency translation adjustments | — |  | (42,725) |  |  | — |  | — |  | — |  | (12) |  |  | (42,737) |
Changes in unrecognized pension gains (losses) and related amortization, net of tax | — |  | 2,150 |  |  | — |  | — |  | — |  | — |  | 2,150 |
Changes in derivative gains (losses), net of tax | — |  | (593) |  |  | — |  | — |  | — |  | — |  | (593) |
Stock awards and option exercises | — |  | — |  | 12 |  |  | 22,436 |  |  | 78,219 |  |  | — |  | 100,667 |
Cash dividends declared on common stock | (67,195) |  |  | — |  | — |  | — |  | — |  | — |  | (67,195) |
Treasury stock purchased | — |  | — |  | — |  | (54,873) |  |  | — |  | — |  | (54,873) |
Balance - September 30, 2019 | $ | 1,498,300 |  |  | $ | (351,672) |  |  | $ | 685 |  |  | $ | (350,645) |  |  | $ | 756,988 |  |  | $ | 323 |  |  | $ | 1,553,979 |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Balance - December 31, 2019 | $ | 1,523,820 |  |  | $ | (341,948) |  |  | $ | 686 |  |  | $ | (381,238) |  |  | $ | 770,596 |  |  | $ | 336 |  |  | $ | 1,572,252 |
Net income | 160,808 |  |  | — |  | — |  | — |  | — |  | 37 |  |  | 160,845 |
Adoption of CECL standard | (1,377) |  |  | — |  | — |  | — |  | — |  | — |  | (1,377) |
Foreign currency translation adjustments | — |  | 19,282 |  |  | — |  | — |  | — |  | 10 |  |  | 19,292 |
Changes in unrecognized pension gains (losses) and related amortization, net of tax | — |  | 4,639 |  |  | — |  | — |  | — |  | — |  | 4,639 |
Changes in derivative gains (losses), net of tax | — |  | 603 |  |  | — |  | — |  | — |  | — |  | 603 |
Stock awards and option exercises | — |  | — |  | 7 |  |  | 16,377 |  |  | 56,677 |  |  | — |  | 73,061 |
Cash dividends declared on common stock | (69,360) |  |  | — |  | — |  | — |  | — |  | — |  | (69,360) |
Balance - September 30, 2020 | $ | 1,613,891 |  |  | $ | (317,424) |  |  | $ | 693 |  |  | $ | (364,861) |  |  | $ | 827,273 |  |  | $ | 383 |  |  | $ | 1,759,955 |

​
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
​
6

Table of Contents
AptarGroup, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
​

In thousands, brackets denote cash outflows | ​ | ​ | ​
​ | ​ | ​ | ​
Nine Months Ended September 30, | 2020 | ​ | 2019
​ | ​ | ​ | ​
Cash Flows from Operating Activities: | ​ | ​ | ​
Net income | $ | 160,845 |  |  | $ | 193,689 |
Adjustments to reconcile net income to net cash provided by operations: | ​ | ​ | ​
Depreciation | 132,394 |  |  | 124,787 |
Amortization | 30,020 |  |  | 19,787 |
Stock-based compensation | 26,191 |  |  | 18,075 |
Provision for CECL | 2,345 |  |  | 930 |
Loss on disposition of fixed assets | 475 |  |  | 303 |
Deferred income taxes | (2,591) |  |  | 5,948 |
Defined benefit plan expense | 17,442 |  |  | 11,517 |
Equity in results of affiliates | 1,383 |  |  | (152) |
Change in fair value of contingent consideration | 4,270 |  |  | — |
Changes in balance sheet items, excluding effects from foreign currency adjustments: | ​ | ​ | ​
Accounts and other receivables | (31,871) |  |  | 724 |
Inventories | 3,937 |  |  | (16,025) |
Prepaid and other current assets | (15,932) |  |  | (1,721) |
Accounts payable, accrued and other liabilities | 64,113 |  |  | 15,047 |
Income taxes payable | (4,865) |  |  | 6,729 |
Retirement and deferred compensation plan liabilities | (1,569) |  |  | (935) |
Other changes, net | (5,160) |  |  | 1,678 |
Net Cash Provided by Operations | 381,427 |  |  | 380,381 |
Cash Flows from Investing Activities: | ​ | ​ | ​
Capital expenditures | (173,365) |  |  | (186,841) |
Proceeds from sale of property, plant and equipment | 2,845 |  |  | 3,658 |
Acquisition of business, net of cash acquired and release of escrow | (164,181) |  | ​ | (49,062) |
Acquisition of intangible assets, net | (3,690) |  |  | (4,621) |
Investment in equity securities | (38,455) |  |  | (3,530) |
Proceeds from sale of investment in equity securities | — |  | ​ | 16,487 |
Notes receivable, net | (1,046) |  |  | (89) |
Net Cash Used by Investing Activities | (377,892) |  |  | (223,998) |
Cash Flows from Financing Activities: | ​ | ​ | ​
Proceeds from notes payable and overdrafts | 19,191 |  | ​ | 36,893 |
Repayments of notes payable and overdrafts | (33,162) |  | ​ | (41,145) |
Proceeds and repayments of short term revolving credit facility, net | 70,000 |  | ​ | (47,253) |
Proceeds from long-term obligations | 1,316 |  |  | 10,524 |
Repayments of long-term obligations | (63,052) |  |  | (64,924) |
Payment of contingent consideration obligation | (2,765) |  | ​ | —
Dividends paid | (69,360) |  |  | (67,195) |
Proceeds from stock option exercises | 51,098 |  |  | 81,815 |
Purchase of treasury stock | — |  | (54,873) |
Net Cash Used by Financing Activities | (26,734) |  |  | (146,158) |
Effect of Exchange Rate Changes on Cash | 7,605 |  |  | (6,471) |
Net (Decrease) Increase in Cash and Equivalents and Restricted Cash | (15,594) |  |  | 3,754 |
Cash and Equivalents and Restricted Cash at Beginning of Period | 246,973 |  |  | 266,823 |
Cash and Equivalents and Restricted Cash at End of Period | $ | 231,379 |  |  | $ | 270,577 |

​
7

Table of Contents
Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow related to the Noble and Fusion Acquisitions (as defined herein).

Nine Months Ended September 30, | 2020 |  | 2019
​ | ​ |  | ​
Cash and equivalents | $ | 226,546 |  |  | $ | 270,577 |
Restricted cash included in prepaid and other | 4,833 |  |  | —
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows | $ | 231,379 |  |  | $ | 270,577 |

​
​
See accompanying unaudited Notes to Condensed Consolidated Financial Statements.
8

Table of Contents
​
​
AptarGroup, Inc.
Notes to Condensed Consolidated Financial Statements
(Dollars in Thousands, Except per Share Amounts, or as Otherwise Indicated)
(Unaudited)
​
NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
​
BASIS OF PRESENTATION
​
The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated. Certain previously reported amounts have been reclassified to conform to the current period presentation.
In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2019 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.
Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. For the nine months ended September 30, 2020, our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues.
There are many uncertainties regarding the current COVID-19 pandemic, including the scope of scientific and health issues, the anticipated duration of the pandemic and the extent of local and worldwide social, political and economic disruption it may cause. The pandemic has impacted certain markets within our business, operations and financial results during the nine months ended September 30, 2020 including an overall reduction to net sales within those markets. No impairments were recorded as of September 30, 2020. While the disruption is currently expected to be temporary, there is uncertainty around the duration. Due to significant uncertainty surrounding the situation, future results could change and therefore our results could be materially impacted.
​
ADOPTION OF RECENT ACCOUNTING STANDARDS
​
Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.
Effective January 1, 2020, we adopted ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, issued by the FASB in June 2016, as well as the clarifying amendments subsequently issued. We applied the guidance using a modified retrospective approach and accordingly recognized an amount of $1.4 million as the cumulative adjustment to opening retained earnings in the first quarter of 2020. This is based on management's best estimates of specific losses on individual exposures particularly on current trade receivables, as well as the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. On an ongoing basis, we will contemplate forward-looking economic conditions in recording lifetime expected credit losses for our financial assets measured at cost, such as our trade receivables and certain other assets.
In January 2017, the FASB issued ASU 2017-04, which provides guidance to simplify how an entity is required to test goodwill for impairm ent by eliminating Step 2 from the goodwill impairment test. As a result, impairment charges are required for the amount by which a reporting unit’s carrying amount exceeds its fair value up to the amount of its allocated goodwill. We adopted the standard on January 1, 2020 and did not record any impairment charges.
9

Table of Contents
In August 2018, the FASB issued ASU 2018-15 to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. We adopted the standard on January 1, 2020 and no material impacts were noted.
In August 2018, the FASB issued ASU 2018-13, which amends disclosure requirements for fair value measurements. The new standard modifies disclosure requirements including removing requirements to disclose the valuation process for Level 3 measurements and adding requirements to disclose the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements and the range and weighted average of significant unobservable inputs used to develop Level 3 measurements. We adopted the standard on January 1, 2020 and no material impacts were noted.
Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.
INCOME TAXES
​
We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where the income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create temporary differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made.
We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested. Under current U.S. tax laws, all of our non-U.S. earnings are subject to U.S. taxation. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and the global cash management goals of the Company.
We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition.
The Company is subject to taxation and files income tax returns in the U.S. federal jurisdiction and many state and foreign jurisdictions. The Company believes that an adequate provision has been made for any adjustments that may result from tax examinations. However, the outcome of tax audits cannot be predicted with certainty. If any issues addressed in the Company’s tax audits are resolved in a manner inconsistent with its expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs. The resolution of each of these audits is not expected to be material to our Condensed Consolidated Financial Statements.
​
​
​
​
​
​
NOTE 2 – REVENUE
At contract inception, we assess the goods and services promised in our contracts with customers and identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product and tooling sales; however, we also receive revenues from service, license, exclusivity and royalty arrangements, which collectively are not material to the quarterly and year-to-date results. Revenue by segment and geography for the three and nine months ended September 30, 2020 and 2019 is as follows:

| For the Three Months Ended September 30, 2020
Segment | Europe |  | Domestic |  | Latin America |  | Asia |  | Total
Beauty + Home | 165,701 |  |  | 109,175 |  |  | 37,921 |  |  | 24,434 |  |  | 337,231 |
Pharma | 206,376 |  |  | 92,932 |  |  | 4,846 |  |  | 11,604 |  |  | 315,758 |
Food + Beverage | 29,688 |  |  | 60,439 |  |  | 6,668 |  |  | 9,369 |  |  | 106,164 |
Total | 401,765 |  |  | 262,546 |  |  | 49,435 |  |  | 45,407 |  |  | 759,153 |

​
10

Table of Contents

| For the Three Months Ended September 30, 2019
Segment | Europe |  | Domestic |  | Latin America |  | Asia |  | Total
Beauty + Home | $ | 188,542 |  |  | $ | 75,931 |  |  | $ | 40,261 |  |  | $ | 23,448 |  |  | $ | 328,182 |
Pharma | 174,252 |  |  | 78,259 |  |  | 6,366 |  |  | 10,374 |  |  | 269,251 |
Food + Beverage | 28,718 |  |  | 57,307 |  |  | 8,058 |  |  | 9,762 |  |  | 103,845 |
Total | $ | 391,512 |  |  | $ | 211,497 |  |  | $ | 54,685 |  |  | $ | 43,584 |  |  | $ | 701,278 |

​

​ | For the Nine Months Ended September 30, 2020
Segment | Europe |  | Domestic |  | Latin America |  | Asia |  | Total
Beauty + Home | $ | 505,063 |  |  | $ | 285,369 |  |  | $ | 103,995 |  |  | $ | 67,150 |  |  | $ | 961,577 |
Pharma | 598,319 |  |  | 264,995 |  |  | 18,412 |  |  | 32,487 |  |  | 914,213 |
Food + Beverage | 86,298 |  |  | 172,507 |  |  | 21,191 |  |  | 24,225 |  |  | 304,221 |
Total | $ | 1,189,680 |  |  | $ | 722,871 |  |  | $ | 143,598 |  |  | $ | 123,862 |  |  | $ | 2,180,011 |

​
​

​ | For the Nine Months Ended September 30, 2019
Segment | Europe |  | Domestic |  | Latin America |  | Asia |  | Total
Beauty + Home | $ | 607,316 |  |  | $ | 236,883 |  |  | $ | 124,352 |  |  | $ | 69,370 |  |  | $ | 1,037,921 |
Pharma | 549,080 |  |  | 226,073 |  |  | 21,100 |  |  | 27,638 |  |  | 823,891 |
Food + Beverage | 92,015 |  |  | 177,587 |  |  | 25,153 |  |  | 31,832 |  |  | 326,587 |
Total | $ | 1,248,411 |  |  | $ | 640,543 |  |  | $ | 170,605 |  |  | $ | 128,840 |  |  | $ | 2,188,399 |

​
We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the receipt of the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped or services are performed and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance.
The opening and closing balances of our contract asset and contract liabilities are as follows:

​ | Balance as of December 31, 2019 |  | Balance as of September 30, 2020 |  | Increase/ (Decrease)
Contract asset (current) | $ | 16,245 |  |  | $ | 15,914 |  |  | $ | (331) |
Contract asset (long-term) | $ | — |  |  | $ | — |  |  | $ | — |
Contract liability (current) | $ | 79,305 |  |  | $ | 66,782 |  |  | $ | (12,523) |
Contract liability (long-term) | $ | 9,779 |  |  | $ | 22,035 |  |  | $ | 12,256 |

​
The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the customer’s payment. The total amount of revenue recognized during the current year against contract liabilities is $59.6 million, including $39.1 million relating to contract liabilities at the beginning of the year.
Determining the Transaction Price
In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled.
11

Table of Contents
Product Sales
We primarily manufacture and sell drug delivery, dispensing, sealing and active packaging solutions. The amount of consideration is typically fixed for such customers. At the time of delivery, the customer is invoiced the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer.
To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. A majority of product sales are sold free on board (“FOB”) shipping point. For FOB shipping point shipments, control of the goods transfers to the customer at the time of shipment of the goods. Therefore, our performance obligation is satisfied at the time of shipment. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale.
There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the Output Method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks.
As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties.
Tooling Sales
We also build, or contract to build molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the Input Method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any material significant payment terms as payment is typically either received during the mold-build process or shortly after completion.
In certain instances, we offer extended warranties on tools sold to our customers above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. At December 31, 2019, $515 thousand of unearned revenue associated with outstanding contracts was reported in Accounts Payable, Accrued and Other Liabilities. At September 30, 2020, the unearned amount was $487 thousand. We expect to recognize approximately $55 thousand of the unearned amount during the remainder of 2020, $131 thousand in 2021, and $301 thousand thereafter.
Credit Risk
We are exposed to credit losses primarily through our product sales, tooling sales and services to our customers. We assess each customer’s ability to pay for the products we sell by conducting a credit review. The credit review considers our expected billing exposure and timing for payment and the customer’s established credit rating or our assessment of the customer’s creditworthiness based on our analysis of their financial statements when a credit rating is not available. We also consider contract terms and conditions, country and political risks, and business strategy in our evaluation. A credit limit is established for each customer based on the outcome of this review.
We monitor our ongoing credit exposure through active review of customer balances against contract terms and due dates. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ collection agencies and legal counsel to pursue recovery of defaulted receivables.
At September 30, 2020, we reported $593 million of accounts receivable, net of CECL of $7.4 million. Changes in the allowance were not material for the nine months ended September 30, 2020. Current uncertainty in credit and market conditions due to the COVID-19 pandemic may slow our collection efforts if customers experience significant difficulty accessing credit and paying their obligations, which may lead to higher than normal accounts receivable and increased CECL charges.
12

Table of Contents
NOTE 3 - INVENTORIES
Inventories, by component, consisted of:​

​ | September 30, 2020 |  | December 31, 2019
Raw materials | $ | 112,296 |  |  | $ | 111,653 |
Work in process | 119,397 |  |  | 123,750 |
Finished goods | 143,484 |  |  | 140,392 |
Total | $ | 375,177 |  |  | $ | 375,795 |

​
NOTE 4 – GOODWILL AND OTHER INTANGIBLE ASSETS
The changes in the carrying amount of goodwill by reporting segment since December 31, 2019 are as follows:​

​ | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Total
Goodwill | $ | 221,658 |  |  | $ | 413,650 |  |  | $ | 128,153 |  |  | $ | 1,615 |  |  | $ | 765,076 |
Accumulated impairment losses | — |  |  | — |  |  | — |  |  | (1,615) |  |  | (1,615) |
Balance as of December 31, 2019 | $ | 221,658 |  |  | $ | 413,650 |  |  | $ | 128,153 |  |  | $ | — |  |  | $ | 763,461 |
Acquisition | 99,350 |  |  | 463 |  |  | — |  |  | — |  |  | 99,813 |
Foreign currency exchange effects | 3,972 |  |  | 10,502 |  |  | 267 |  |  | — |  |  | 14,741 |
Goodwill | $ | 324,980 |  |  | $ | 424,615 |  |  | $ | 128,420 |  |  | $ | 1,615 |  |  | $ | 879,630 |
Accumulated impairment losses | — |  |  | — |  |  | — |  |  | (1,615) |  |  | (1,615) |
Balance as of September 30, 2020 | $ | 324,980 |  |  | $ | 424,615 |  |  | $ | 128,420 |  |  | $ | — |  |  | $ | 878,015 |

​
The table below shows a summary of intangible assets as of September 30, 2020 and December 31, 2019.
​​

​ | ​ |  | September 30, 2020 |  | December 31, 2019
Weighted Average Amortization Period (Years) |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Value |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Value
Amortized intangible assets: | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Patents | 7.4 |  | $ | 2,795 |  |  | (1,393) |  |  | $ | 1,402 |  |  | $ | 2,804 |  |  | $ | (1,318) |  |  | $ | 1,486 |
Acquired technology | 12.9 |  | 107,529 |  |  | (33,322) |  |  | 74,207 |  |  | 100,511 |  |  | (25,430) |  |  | 75,081 |
Customer relationships | 13.3 |  | 283,091 |  |  | (50,048) |  |  | 233,043 |  |  | 217,934 |  |  | (33,924) |  |  | 184,010 |
Trademarks and trade names | 6.3 |  | 45,285 |  |  | (15,470) |  |  | 29,815 |  |  | 35,015 |  |  | (11,003) |  |  | 24,012 |
License agreements and other | 19.1 |  | 18,693 |  |  | (9,465) |  |  | 9,228 |  |  | 16,153 |  |  | (9,658) |  |  | 6,495 |
Total intangible assets | 12.6 |  | $ | 457,393 |  |  | $ | (109,698) |  |  | $ | 347,695 |  |  | $ | 372,417 |  |  | $ | (81,333) |  |  | $ | 291,084 |

​
Aggregate amortization expense for the intangible assets above for the quarters ended September 30, 2020 and 2019 was $9,686 and $7,399, respectively. Aggregate amortization expense for the intangible assets above for the nine months ended September 30, 2020 and 2019 was $30,020 and $19,787, respectively.
13

Table of Contents
Future estimated amortization expense for the years ending December 31 is as follows:

2020 | $ | 9,819 |  |  | (remaining estimated amortization for 2020)
2021 | 38,300 |  |  | ​
2022 | 38,020 |  |  | ​
2023 | 37,938 |  |  | ​
2024 and thereafter | 223,618 |  |  | ​

​
Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of September 30, 2020.​
NOTE 5 – INCOME TAXES
The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items.
The effective tax rate for the three months ended September 30, 2020 and 2019, respectively, was 28.5% and 31.0%. The reported effective tax rate for the three months ended September 30, 2020 was favorably impacted by additional excess tax benefits from employee stock-based compensation of $1.4 million and benefits reflecting changes in the U.S. global intangible low taxed income ("U.S. GILTI") tax for the current year of $1.5 million.
The effective tax rate for the nine months ended September 30, 2020 and 2019 was 29.4%. The nine month effective tax rates reflect a favorable impact from the excess tax benefits from employee stock-based compensation of $8.7 million and $13.6 million, respectively, offset by the unfavorable impact from losses in jurisdictions where the tax benefit is not recognized and other discrete items of $5.1 million and $10.9 million, respectively.
​
NOTE 6 – DEBT
Notes Payable, Revolving Credit Facility and Overdrafts
At September 30, 2020 and December 31, 2019, our notes payable, revolving credit facility and overdrafts, consisted of the following:

​ | September 30, 2020 |  | December 31, 2019
Notes payable 8% | $ | 200 |  |  | $ | 1,436 |
Revolving credit facility 1.46% | 95,000 |  |  | 25,000 |
Overdrafts 5.68% - 7.82% | — |  |  | 17,823 |
​ | $ | 95,200 |  |  | $ | 44,259 |

​
We maintain a multi-currency revolving credit facility with two tranches that matures in July 2022 which provides for unsecured financing of up to $300 million that is available in the U.S. and up to €150 million that is available to our wholly-owned UK subsidiary. $95.0 million was utilized under our U.S. facility and no balance was utilized under our euro-based revolving credit facility as of September 30, 2020. $25.0 million was utilized under our U.S. facility and no balance was utilized on our euro-based revolving credit facility as of December 31, 2019.
There are no compensating balance requirements associated with our revolving credit facility. Each borrowing under the credit facility will bear interest at rates based on LIBOR, prime rates or other similar rates, in each case plus an applicable margin. A facility fee on the total amount of the facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio.
14

Table of Contents
Long-Term Obligations
At September 30, 2020, our long-term obligations consisted of the following:

​ | Principal |  | Unamortized Debt Issuance Costs |  | Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028 | $ | 13,993 |  |  | $ | — |  |  | $ | 13,993 |
Senior unsecured notes 3.2%, due in 2022 | 75,000 |  |  | 44 |  |  | 74,956 |
Senior unsecured debts 1.8% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022 | 112,000 |  |  | 277 |  |  | 111,723 |
Senior unsecured notes 3.5%, due in 2023 | 125,000 |  |  | 116 |  |  | 124,884 |
Senior unsecured notes 1.0%, due in 2023 | 117,230 |  |  | 312 |  |  | 116,918 |
Senior unsecured notes 3.4%, due in 2024 | 50,000 |  |  | 53 |  |  | 49,947 |
Senior unsecured notes 3.5%, due in 2024 | 100,000 |  |  | 116 |  |  | 99,884 |
Senior unsecured notes 1.2%, due in 2024 | 234,460 |  |  | 621 |  |  | 233,839 |
Senior unsecured notes 3.6%, due in 2025 | 125,000 |  |  | 134 |  |  | 124,866 |
Senior unsecured notes 3.6%, due in 2026 | 125,000 |  |  | 134 |  |  | 124,866 |
Finance Lease Liabilities | 30,115 |  |  | — |  |  | 30,115 |
​ | $ | 1,107,798 |  |  | $ | 1,807 |  |  | $ | 1,105,991 |
Current maturities of long-term obligations | (66,056) |  |  | — |  |  | (66,056) |
Total long-term obligations | $ | 1,041,742 |  |  | $ | 1,807 |  |  | $ | 1,039,935 |

​
At December 31, 2019, our long-term obligations consisted of the following:
​

| Principal |  | Unamortized Debt Issuance Costs |  | Net
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028 | $ | 19,220 |  |  | $ | — |  |  | $ | 19,220 |
Senior unsecured notes 3.2%, due in 2022 | 75,000 |  |  | 64 |  |  | 74,936 |
Senior unsecured debts 3.2% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022 | 168,000 |  |  | 390 |  |  | 167,610 |
Senior unsecured notes 3.5%, due in 2023 | 125,000 |  |  | 144 |  |  | 124,856 |
Senior unsecured notes 1.0%, due in 2023 | 112,170 |  |  | 356 |  |  | 111,814 |
Senior unsecured notes 3.4%, due in 2024 | 50,000 |  |  | 63 |  |  | 49,937 |
Senior unsecured notes 3.5%, due in 2024 | 100,000 |  |  | 144 |  |  | 99,856 |
Senior unsecured notes 1.2%, due in 2024 | 224,340 |  |  | 742 |  |  | 223,598 |
Senior unsecured notes 3.6%, due in 2025 | 125,000 |  |  | 169 |  |  | 124,831 |
Senior unsecured notes 3.6%, due in 2026 | 125,000 |  |  | 169 |  |  | 124,831 |
Finance Lease Liabilities | 29,952 |  |  | — |  |  | 29,952 |
​ | $ | 1,153,682 |  |  | $ | 2,241 |  |  | $ | 1,151,441 |
Current maturities of long-term obligations | (65,988) |  |  | — |  |  | (65,988) |
Total long-term obligations | $ | 1,087,694 |  |  | $ | 2,241 |  |  | $ | 1,085,453 |

​
The aggregate long-term maturities, excluding finance lease liabilities, which are disclosed in Note 7, due annually from the current balance sheet date for the next five years are $62,023, $134,772, $119,655, $510,581, $229 and $250,423 thereafter.
15

Table of Contents
Covenants
Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

​ |  | Requirement |  | Level at September 30, 2020
Consolidated Leverage Ratio (1) |  | Maximum of 3.50 to 1.00 |  | 1.81 to 1.00
Consolidated Interest Coverage Ratio (1) |  | Minimum of 3.00 to 1.00 |  | 15.92 to 1.00

________________________________________
(1)Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.
​
​
NOTE 7 – LEASES
We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2034. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.
Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”).
The components of lease expense for the three and nine months ended September 30, 2020 and 2019 were as follows:​

​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Operating lease cost | $ | 6,076 |  |  | $ | 6,001 |  |  | $ | 17,171 |  |  | $ | 17,442 |
​ | ​ |  | ​ |  | ​ |  | ​
Finance lease cost: | ​ |  | ​ |  | ​ |  | ​
Amortization of right-of-use assets | $ | 905 |  |  | $ | 1,165 |  |  | $ | 3,010 |  |  | $ | 3,041 |
Interest on lease liabilities | $ | 356 |  |  | $ | 344 |  |  | $ | 1,073 |  |  | $ | 984 |
Total finance lease cost | $ | 1,261 |  |  | $ | 1,509 |  |  | $ | 4,083 |  |  | $ | 4,025 |
​ | ​ |  | ​ |  | ​ |  | ​
Short-term lease and variable lease costs | $ | 2,466 |  |  | $ | 1,757 |  |  | $ | 7,344 |  |  | $ | 6,027 |

​
Supplemental cash flow information related to leases was as follows:

Nine Months Ended September 30, | 2020 |  | 2019
Cash paid for amounts included in the measurement of lease liabilities: | ​ |  | ​
Operating cash flows from operating leases | $ | 17,060 |  |  | $ | 15,874 |
Operating cash flows from finance leases | 1,089 |  |  | 877 |
Financing cash flows from finance leases | 3,678 |  |  | 3,365 |
​ |  |  |
Right-of-use assets obtained in exchange for lease obligations: |  |  |
Operating leases | $ | 19,255 |  |  | $ | 11,673 |
Finance leases | 3,356 |  |  | 12,401 |

​
16

Table of Contents
NOTE 8 – RETIREMENT AND DEFERRED COMPENSATION PLANS
Components of Net Periodic Benefit Cost:

​ | Domestic Plans |  | Foreign Plans
Three Months Ended September 30, | 2020 |  | 2019 |  | 2020 |  | 2019
Service cost | $ | 3,570 |  |  | $ | 2,772 |  |  | $ | 1,867 |  |  | $ | 1,429 |
Interest cost | 1,761 |  |  | 1,845 |  |  | 360 |  |  | 491 |
Expected return on plan assets | (3,062) |  |  | (3,095) |  |  | (671) |  |  | (581) |
Amortization of net loss | 1,422 |  |  | 490 |  |  | 544 |  |  | 356 |
Amortization of prior service cost | — |  |  | — |  |  | 101 |  |  | 111 |
Net periodic benefit cost | $ | 3,691 |  |  | $ | 2,012 |  |  | $ | 2,201 |  |  | $ | 1,806 |

​

​ | Domestic Plans |  | Foreign Plans
Nine Months Ended September 30, | 2020 |  | 2019 |  | 2020 |  | 2019
Service cost | $ | 10,709 |  |  | $ | 8,320 |  |  | $ | 5,402 |  |  | $ | 4,334 |
Interest cost | 5,284 |  |  | 5,536 |  |  | 1,040 |  |  | 1,487 |
Expected return on plan assets | (9,186) |  |  | (9,284) |  |  | (1,936) |  |  | (1,759) |
Amortization of net loss | 4,264 |  |  | 1,468 |  |  | 1,572 |  |  | 1,078 |
Amortization of prior service cost | — |  |  | — |  |  | 293 |  |  | 337 |
Net periodic benefit cost | $ | 11,071 |  |  | $ | 6,040 |  |  | $ | 6,371 |  |  | $ | 5,477 |

​
The components of net periodic benefit cost, other than the service cost component, are included in the line “Miscellaneous, net” in the income statement.
EMPLOYER CONTRIBUTIONS
Although we currently have no minimum funding requirements for our domestic and foreign plans, we contributed $204 thousand to our ongoing domestic supplemental employee retirement plan (SERP) annuity contracts during the nine months ended September 30, 2020 and do not expect additional significant contributions during 2020. We have contributed approximately $1.6 million to our foreign defined benefit plans during the nine months ended September 30, 2020 and do not expect additional significant contributions during 2020.
​
NOTE 9 – ACCUMULATED OTHER COMPREHENSIVE INCOME
Changes in Accumulated Other Comprehensive (Loss) Income by Component:

​ | Foreign Currency |  | Defined Benefit Pension Plans |  | Derivatives |  | Total
Balance - December 31, 2018 | $ | (248,401) |  |  | $ | (60,463) |  |  | $ | (1,640) |  |  | $ | (310,504) |
Other comprehensive (loss) income before reclassifications | (42,725) |  |  | — |  |  | 11,806 |  |  | (30,919) |
Amounts reclassified from accumulated other comprehensive income (loss) | — |  |  | 2,150 |  |  | (12,399) |  |  | (10,249) |
Net current-period other comprehensive (loss) income | (42,725) |  |  | 2,150 |  |  | (593) |  |  | (41,168) |
Balance - September 30, 2019 | $ | (291,126) |  |  | $ | (58,313) |  |  | $ | (2,233) |  |  | $ | (351,672) |
​ |  |  |  |  |  |  |
Balance - December 31, 2019 | $ | (257,124) |  |  | $ | (83,147) |  |  | $ | (1,677) |  |  | $ | (341,948) |
Other comprehensive income (loss) before reclassifications | 19,282 |  |  | — |  |  | (4,342) |  |  | 14,940 |
Amounts reclassified from accumulated other comprehensive income | — |  |  | 4,639 |  |  | 4,945 |  |  | 9,584 |
Net current-period other comprehensive income | 19,282 |  |  | 4,639 |  |  | 603 |  |  | 24,524 |
Balance - September 30, 2020 | $ | (237,842) |  |  | $ | (78,508) |  |  | $ | (1,074) |  |  | $ | (317,424) |

17

Table of Contents
​
Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:

Details about Accumulated Other Comprehensive Income Components | Amount Reclassified from Accumulated Other Comprehensive Income |  | Affected Line in the Statement Where Net Income is Presented
Three Months Ended September 30, | 2020 |  | 2019 |  |
​ | ​ |  | ​ |  | ​
Defined Benefit Pension Plans | ​ |  | ​ |  | ​
Amortization of net loss | $ | 1,966 |  |  | $ | 846 |  |  | (1)
Amortization of prior service cost | 101 |  |  | 111 |  |  | (1)
​ | 2,067 |  |  | 957 |  |  | Total before tax
​ | (504) |  |  | (244) |  |  | Tax impact
​ | $ | 1,563 |  |  | $ | 713 |  |  | Net of tax
Derivatives | ​ |  | ​ |  | ​
Changes in cross currency swap: interest component | $ | (146) |  |  | $ | (1,309) |  |  | Interest Expense
Changes in cross currency swap: foreign exchange component | 6,099 |  |  | (6,491) |  |  | Miscellaneous, net
​ | $ | 5,953 |  |  | $ | (7,800) |  |  | Net of tax
Total reclassifications for the period | $ | 7,516 |  |  | $ | (7,087) |  |  | ​

Details about Accumulated Other Comprehensive Income Components | Amount Reclassified from Accumulated Other Comprehensive Income |  | Affected Line in the Statement Where Net Income is Presented
Nine Months Ended September 30, | 2020 |  | 2019 |  |
​ | ​ |  | ​ |  | ​
Defined Benefit Pension Plans | ​ |  | ​ |  | ​
Amortization of net loss | $ | 5,836 |  |  | $ | 2,546 |  |  | (1)
Amortization of prior service cost | 293 |  |  | 337 |  |  | (1)
​ | 6,129 |  |  | 2,883 |  |  | Total before tax
​ | (1,490) |  |  | (733) |  |  | Tax impact
​ | $ | 4,639 |  |  | $ | 2,150 |  |  | Net of tax
Derivatives | ​ |  | ​ |  | ​
Changes in cross currency swap: interest component | $ | (1,434) |  |  | $ | (4,315) |  |  | Interest Expense
Changes in cross currency swap: foreign exchange component | 6,379 |  |  | (8,084) |  |  | Miscellaneous, net
​ | $ | 4,945 |  |  | $ | (12,399) |  |  | Net of tax
Total reclassifications for the period | $ | 9,584 |  |  | $ | (10,249) |  |  | ​

______________________________________________
(1)These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.
​
​
​
NOTE 10 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.
18

Table of Contents
For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets. See Note 11 - Fair Value for additional details.
Cash Flow Hedge
For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows.
During 2017, our wholly-owned UK subsidiary borrowed $280 million in term loan borrowings under a new credit facility. In order to mitigate the currency risk of U.S. dollar debt on a euro functional currency entity and to mitigate the risk of variability in interest rates, we entered into a cross currency swap in the notional amount of $280 million to effectively hedge the foreign exchange and interest rate exposure on the $280 million term loan. This EUR/USD swap agreement fixed our U.S. dollar floating-rate debt to 1.36% euro fixed-rate debt. Related to this hedge, approximately $1.1 million of loss is included in accumulated other comprehensive loss at September 30, 2020. The amount expected to be recognized into earnings during the next 12 months related to the interest component of our cross currency swap based on prevailing foreign exchange and interest rates at September 30, 2020 is a gain of $0.1 million. The amount expected to be recognized into earnings during the next 12 months related to the foreign exchange component of our cross currency swap is dependent on fluctuations in currency exchange rates. As of September 30, 2020, the fair values of the cross currency swap were a $3.2 million liability. The swap contract expires on July 20, 2022.
Hedge of Net Investments in Foreign Operations
A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we maintain debt in these subsidiaries to offset the net asset exposure. We do not otherwise actively manage this risk using derivative financial instruments. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.
Other
As of September 30, 2020, we have recorded the fair value of foreign currency forward exchange contracts of $0.1 million in prepaid and other and $0.4 million in accounts payable, accrued and other liabilities on the balance sheet. All forward exchange contracts outstanding as of September 30, 2020 had an aggregate notional contract amount of $43.2 million.
19

Table of Contents
​

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019

​ | ​ |  | September 30, 2020 |  | December 31, 2019
​ | Balance Sheet Location |  | Derivatives Designated as Hedging Instruments |  | Derivatives not Designated as Hedging Instruments |  | Derivatives Designated as Hedging Instruments |  | Derivatives not Designated as Hedging Instruments
Derivative Assets | ​ |  | ​ |  | ​ |  | ​ |  | ​
Foreign Exchange Contracts | Prepaid and other |  | $ | — |  |  | $ | 73 |  |  | — |  | $ | 206 |
Cross Currency Swap Contract (1) | Prepaid and other |  | — |  |  | — |  |  | 2,552 |  |  | — |
​ | ​ |  | $ | — |  |  | $ | 73 |  |  | $ | 2,552 |  |  | $ | 206 |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​
Derivative Liabilities | ​ |  | ​ |  | ​ |  | ​ |  | ​
Foreign Exchange Contracts | Accounts payable, accrued and other liabilities |  | $ | — |  |  | $ | 426 |  |  | $ | — |  |  | $ | 401 |
Cross Currency Swap Contract (1) | Accounts payable, accrued and other liabilities |  | 3,227 |  |  | — |  |  | — |  |  | — |
​ | ​ |  | $ | 3,227 |  |  | $ | 426 |  |  | $ | — |  |  | $ | 401 |

__________________________
(1)This cross currency swap contract is composed of both an interest component and a foreign exchange component.
​
​

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Three Months Ended September 30, 2020 and 2019
​

Derivatives in Cash Flow Hedging Relationships | Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative |  | Location of (Loss) Gain Recognized in Income on Derivatives |  | Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative |  | Total Amount of Affected Income Statement Line Item
​ | 2020 |  | 2019 |  | ​ |  | 2020 |  | 2019 |  |
Cross currency swap contract: | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Interest component | $ | (1) |  |  | $ | 1,586 |  |  | Interest expense |  | $ | 146 |  |  | $ | 1,309 |  |  | $ | (8,851) |
Foreign exchange component | (6,099) |  |  | 6,491 |  |  | Miscellaneous, net |  | (6,099) |  |  | 6,491 |  |  | (1,040) |
​ | $ | (6,100) |  |  | $ | 8,077 |  |  | ​ |  | $ | (5,953) |  |  | $ | 7,800 |  |  | ​

​

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, 2020 and 2019

Derivatives in Cash Flow Hedging Relationships | Amount of Gain (Loss) Recognized in Other Comprehensive Income on Derivative |  | Location of (Loss) Gain Recognized in Income on Derivatives |  | Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Income on Derivative |  | Total Amount of Affected Income Statement Line Item
​ | 2020 |  | 2019 |  | ​ |  | 2020 |  | 2019 |  |
Cross currency swap contract: | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Interest component | $ | 2,037 |  |  | $ | 4,058 |  |  | Interest expense |  | $ | 1,434 |  |  | $ | 4,315 |  |  | $ | (25,973) |
Foreign exchange component | (6,379) |  |  | 8,084 |  |  | Miscellaneous, net |  | (6,379) |  |  | 8,084 |  |  | (3,375) |
​ | $ | (4,342) |  |  | $ | 12,142 |  |  | ​ |  | $ | (4,945) |  |  | $ | 12,399 |  |  | ​

20

Table of Contents
​
​

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Three Months Ended September 30, 2020 and 2019

Derivatives Not Designated as Hedging Instruments | Location of (Loss) Gain Recognized in Income on Derivatives |  | Amount of (Loss) Gain Recognized in Income on Derivatives
​ | ​ |  | 2020 |  | 2019
Foreign Exchange Contracts | Other (Expense) Income: Miscellaneous, net |  | $ | (994) |  |  | $ | (15) |
​ | ​ |  | $ | (994) |  |  | $ | (15) |

​
​

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, 2020 and 2019
​

Derivatives Not Designated as Hedging Instruments | Location of (Loss) Gain Recognized in Income on Derivatives |  | Amount of (Loss) Gain Recognized in Income on Derivatives
​ | ​ |  | 2020 |  | 2019
Foreign Exchange Contracts | Other (Expense) Income: Miscellaneous, net |  | $ | (187) |  |  | $ | (529) |
​ | ​ |  | $ | (187) |  |  | $ | (529) |

​
​

​ | ​ |  |  |  |  |  | Gross Amounts not Offset in the Statement of Financial Position |  | ​
​ | Gross Amount |  | Gross Amounts Offset in the Statement of Financial Position |  | Net Amounts Presented in the Statement of Financial Position |  | Financial Instruments |  | Cash Collateral Received |  | Net Amount
Description | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
September 30, 2020
Derivative Assets | $ | 73 |  |  | — |  |  | $ | 73 |  |  | — |  |  | — |  |  | $ | 73 |
Total Assets | $ | 73 |  |  | — |  |  | $ | 73 |  |  | — |  |  | — |  |  | $ | 73 |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Derivative Liabilities | $ | 3,653 |  |  | — |  |  | $ | 3,653 |  |  | — |  |  | — |  |  | $ | 3,653 |
Total Liabilities | $ | 3,653 |  |  | — |  |  | $ | 3,653 |  |  | — |  |  | — |  |  | $ | 3,653 |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
December 31, 2019
Derivative Assets | $ | 2,758 |  |  | — |  |  | $ | 2,758 |  |  | — |  |  | — |  |  | $ | 2,758 |
Total Assets | $ | 2,758 |  |  | — |  |  | $ | 2,758 |  |  | — |  |  | — |  |  | $ | 2,758 |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Derivative Liabilities | $ | 401 |  |  | — |  |  | $ | 401 |  |  | — |  |  | — |  |  | $ | 401 |
Total Liabilities | $ | 401 |  |  | — |  |  | $ | 401 |  |  | — |  |  | — |  |  | $ | 401 |

​
21

Table of Contents
NOTE 11 – FAIR VALUE
Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:
•Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.
•Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.
•Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.
As of September 30, 2020, the fair values of our financial assets and liabilities were categorized as follows:

​ | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets | ​ |  | ​ |  | ​ |  | ​
Foreign exchange contracts (1) | $ | 73 |  |  | $ | — |  |  | $ | 73 |  |  | $ | — |
Total assets at fair value | $ | 73 |  |  | $ | — |  |  | $ | 73 |  |  | $ | — |
Liabilities | ​ |  | ​ |  | ​ |  | ​
Foreign exchange contracts (1) | $ | 426 |  |  | $ | — |  |  | $ | 426 |  |  | $ | — |
Cross currency swap contract (1) | 3,227 |  |  | — |  |  | 3,227 |  |  | — |
Contingent consideration obligation | 26,280 |  |  | — |  |  | — |  |  | 26,280 |
Total liabilities at fair value | $ | 29,933 |  |  | $ | — |  |  | $ | 3,653 |  |  | $ | 26,280 |

​
As of December 31, 2019, the fair values of our financial assets and liabilities were categorized as follows:

​ | Total |  | Level 1 |  | Level 2 |  | Level 3
Assets | ​ |  | ​ |  | ​ |  | ​
Foreign exchange contracts (1) | $ | 206 |  |  | $ | — |  |  | $ | 206 |  |  | $ | — |
Cross currency swap contract (1) | 2,552 |  |  | — |  |  | 2,552 |  |  | — |
Total assets at fair value | $ | 2,758 |  |  | $ | — |  |  | $ | 2,758 |  |  | $ | — |
Liabilities | ​ |  | ​ |  | ​ |  | ​
Foreign exchange contracts (1) | $ | 401 |  |  | $ | — |  |  | $ | 401 |  |  | $ | — |
Contingent consideration obligation | 5,930 |  |  | — |  |  | — |  |  | 5,930 |
Total liabilities at fair value | $ | 6,331 |  |  | $ | — |  |  | $ | 401 |  |  | $ | 5,930 |

________________________________________________
(1)Market approach valuation technique based on observable market transactions of spot and forward rates.
​
The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instruments. We consider our long-term obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $1.1 billion as of September 30, 2020 and $1.1 billion as of December 31, 2019.
As discussed in Note 17 - Acquisitions, we have a contingent consideration obligation to the selling equity holders of Fusion in connection with the Fusion Acquisition (as defined herein) based on 2022 cumulative performance targets, a contingent consideration obligation to the selling equity holders of Noble in connection with the Noble Acquisition (as defined herein) based on 2024 cumulative performance targets and a contingent consideration obligation to the selling equity holder of Gateway in connection with the Gateway Acquisition (as defined herein) based on 2020 and 2022 performance targets. We consider these obligations Level 3 liabilities and have estimated the aggregate fair value for these contingent consideration arrangements to be $22.1 million and $4.2 million for the Fusion Acquisition and the Noble Acquisition, respectively, as of September 30, 2020. During the quarter ended September 30, 2020, $1.3 million of the Gateway contingent consideration accrual was paid out in full satisfaction of the remaining earn out consideration and no related liability is outstanding as all required payments have been made for both performance targets. As of December 31, 2019 the aggregate fair value for these contingent consideration arrangements was $2.9 million and $3.0 million for the Noble Acquisition and the Gateway Acquisition, respectively.
​
22

Table of Contents
NOTE 12 - COMMITMENTS AND CONTINGENCIES
The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur and could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.
Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of September 30, 2020 and December 31, 2019.
A fire caused damage to our facility in Annecy, France in June 2016. We are insured for the damages caused by the fire, including business interruption insurance. For the nine months ended September 30, 2020, we did not receive any insurance proceeds, and have no insurance receivable as of September 30, 2020. During the nine months ended September 30, 2020 and 2019, profitability was not impacted. The final settlement continues to be negotiated. In many cases, our insurance coverage exceeds the amount of our recognized losses. However, no gain contingencies were recognized during the nine months ended September 30, 2020 as our ability to realize those gains remains uncertain.
An environmental investigation, undertaken to assess areas of possible contamination, was completed at our facility in Jundiaí, São Paulo, Brazil. The facility is primarily an internal supplier of anodized aluminum components for certain of our dispensing systems. The testing indicated that soil and groundwater in certain areas of the facility were impacted above acceptable levels established by local regulations. In March 2017, we reported the findings to the relevant environmental authority, the Environmental Company of the State of São Paulo – CETESB. Based upon our best estimate, we recorded a reserve of $1.5 million (operating expense) in the first quarter of 2017 related to this contingency. During 2019, we paid approximately $0.6 million. For the nine months ended September 30, 2020, we paid approximately $0.1 million. As of September 30, 2020, our outstanding reserve is $0.4 million. The ultimate loss associated with this environmental contingency is subject to the investigation and ongoing review of the CETESB. We will continue to evaluate the range of likely costs as the investigation proceeds and we have further clarity on the nature and extent of remediation that will be required. We note that the contamination, or any failure to complete any required remediation in a timely manner, could potentially result in fines or penalties.
In March 2017, the Supreme Court of Brazil issued a decision that a certain state value added tax should not be included in the calculation of federal gross receipts taxes. The decision reduces our gross receipts tax in Brazil prospectively and, potentially, retrospectively. During the first quarter of 2019, we received a favorable court decision of $2.7 million for the retrospective right to recover part of our claim. This amount is recorded in cost of sales as a favorable impact of $1.7 million and $1.0 million was recognized as interest income. In June 2020, we received a favorable court decision of $0.7 million for the retrospective right to recover part of our claim. This amount is recorded in cost of sales as a favorable impact of $0.7 million. If the Supreme Court grants full retrospective recovery, we estimate remaining potential recoveries of approximately $1.5 million to $7.5 million, including interest, depending on the future decisions of the Supreme Court of Brazil. Due to uncertainties around our remaining court recovery claims, we have not recorded any further amounts relating to the retrospective nature of this matter.
In December 2019, tax authorities in Brazil notified us of a tax assessment of approximately $6.1 million, including interest and penalties of $2.3 million and $0.8 million, respectively, relating to differences in tax classification codes used for import duties for the period from January 2015 to August 2018. We are vigorously contesting the assessment, including interest and penalties, and have filed an administrative defense appeal in December 2019. In June 2020, an unfavorable decision was issued on the first administrative defense appeal. We filed a second administrative defense appeal in August 2020. We still believe we have a strong defense. Due to uncertainty in the amount of assessment and the timing of our appeal, no liability is recorded as of September 30, 2020.
​
NOTE 13 – STOCK REPURCHASE PROGRAM
On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
During the three and nine months ended September 30, 2020, we did not repurchase any shares. During the three and nine months ended September 30, 2019, we repurchased approximately 300 thousand shares and 493 thousand shares for approximately $35.8 million and $54.9 million, respectively. As of September 30, 2020, there was $278.5 million of authorized share repurchases available to us.
​
23

Table of Contents
NOTE 14 – STOCK-BASED COMPENSATION
We issue restricted stock units (“RSUs”), which consist of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. Performance-based RSUs have one of two vesting conditions: (1) based on our internal financial performance metrics and (2) based on our total shareholder return (“TSR”) relative to total shareholder returns of an industrial peer group. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest over one year.
The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.
​

Nine Months Ended September 30, | 2020 |  | 2019
Fair value per stock award | $ | 94.98 |  |  | $ | 134.97 |
Grant date stock price | $ | 83.93 |  |  | $ | 104.51 |
Assumptions: | ​ |  | ​
Aptar's stock price expected volatility | 23.80 | % |  | 16.50 | %
Expected average volatility of peer companies | 48.50 | % |  | 31.90 | %
Correlation assumption | 63.50 | % |  | 37.40 | %
Risk-free interest rate | 0.31 | % |  | 2.19 | %
Dividend yield assumption | 1.72 | % |  | 1.30 | %

​
A summary of RSU activity as of September 30, 2020 and changes during the nine month period then ended is presented below:

​ | Time-Based RSUs |  | Performance-Based RSUs
​ | Units |  | Weighted Average Grant-Date Fair Value |  | Units |  | Weighted Average Grant-Date Fair Value
Nonvested at January 1, 2020 | 480,729 |  |  | $ | 95.45 |  |  | 181,680 |  |  | $ | 117.26 |
Granted | 232,802 |  |  | 86.05 |  |  | 417,313 |  |  | 93.08 |
Vested | (130,654) |  |  | 85.62 |  |  | — |  |  | — |
Forfeited | (5,692) |  |  | 99.08 |  |  | (6,714) |  |  | 108.10 |
Nonvested at September 30, 2020 | 577,185 |  |  | $ | 92.33 |  |  | 592,279 |  |  | $ | 100.29 |

​
Included in the September 30, 2020 time-based RSUs are 12,379 units granted to non-employee directors and 11,490 units vested related to non-employee directors.
Compensation expense recorded attributable to RSUs for the first nine months of 2020 and 2019 was approximately $24.5 million and $13.7 million, respectively. The actual tax benefit realized for the tax deduction from RSUs was approximately $4.5 million in the nine months ended September 30, 2020. The fair value of units vested during the nine months ended September 30, 2020 and 2019 was $11.2 million and $4.1 million, respectively. The intrinsic value of units vested during the nine months ended September 30, 2020 and 2019 was $13.5 million and $4.9 million, respectively. As of September 30, 2020, there was $51.1 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 2.0 years.
Historically we issued stock options to our employees and non-employee directors. Beginning in 2019, we no longer issue stock options. Stock options were awarded with the exercise price equal to the market price on the date of grant and generally vest over three years and expire 10 years after grant. Compensation expense attributable to employee stock options for the first nine months of 2020 was approximately $1.7 million ($1.3 million after tax). Approximately $1.4 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. Compensation expense attributable to stock options for the first nine months of 2019 was approximately $4.4 million ($3.6 million after tax). Approximately $3.7 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. The reduction in stock option expense is due to our move to RSUs as discussed above. For stock option grants, we used historical data to estimate expected life and volatility.
24

Table of Contents
A summary of option activity under our stock plans during the nine months ended September 30, 2020 is presented below:​

​ | Stock Awards Plans |  | Director Stock Option Plans
​ | Options |  | Weighted Average Exercise Price |  | Options |  | Weighted Average Exercise Price
Outstanding, January 1, 2020 | 5,044,180 |  |  | $ | 68.32 |  |  | 135,251 |  |  | $ | 58.45 |
Granted | — |  |  | — |  |  | — |  |  | — |
Exercised | (785,478) |  |  | 59.98 |  |  | (34,151) |  |  | 51.75 |
Forfeited or expired | (14,200) |  |  | 76.07 |  |  | — |  |  | — |
Outstanding at September 30, 2020 | 4,244,502 |  |  | $ | 69.91 |  |  | 101,100 |  |  | $ | 60.71 |
Exercisable at September 30, 2020 | 4,089,846 |  |  | $ | 69.11 |  |  | 101,100 |  |  | $ | 60.71 |
Weighted-Average Remaining Contractual Term (Years): | ​ |  | ​ |  | ​ |  | ​
Outstanding at September 30, 2020 | 4.9 |  | ​ |  | 2.9 |  | ​
Exercisable at September 30, 2020 | 4.8 |  | ​ |  | 2.9 |  | ​
Aggregate Intrinsic Value: | ​ |  | ​ |  | ​ |  | ​
Outstanding at September 30, 2020 | $ | 183,753 |  |  | ​ |  | $ | 5,306 |  |  | ​
Exercisable at September 30, 2020 | $ | 179,771 |  |  | ​ |  | $ | 5,306 |  |  | ​
Intrinsic Value of Options Exercised During the Nine Months Ended: | ​ |  | ​ |  | ​ |  | ​
September 30, 2020 | $ | 44,086 |  |  | ​ |  | $ | 2,183 |  |  | ​
September 30, 2019 | $ | 76,797 |  |  | ​ |  | $ | 722 |  |  | ​

​
The grant date fair value of options vested during the nine months ended September 30, 2020 and 2019 was $7.6 million and $12.2 million, respectively. Cash received from option exercises was approximately $51.1 million and the actual tax benefit realized for the tax deduction from option exercises was approximately $10.8 million in the nine months ended September 30, 2020. As of September 30, 2020, the remaining valuation of stock option awards to be expensed in future periods was $0.6 million and the related weighted-average period over which it is expected to be recognized is 0.4 years.
​
​
NOTE 15 – EARNINGS PER SHARE
Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2020 and 2019 is as follows:
​
​
25

Table of Contents

​ | Three Months Ended
​ | September 30, 2020 |  | September 30, 2019
​ | Diluted |  | Basic |  | Diluted |  | Basic
Consolidated operations | ​ |  | ​ |  | ​ |  | ​
Income available to common stockholders | $ | 63,716 |  |  | $ | 63,716 |  |  | $ | 56,750 |  |  | $ | 56,750 |
​ | ​ |  | ​ |  | ​ |  | ​
Average equivalent shares | ​ |  | ​ |  | ​ |  | ​
Shares of common stock | 64,562 |  |  | 64,562 |  |  | 64,010 |  |  | 64,010 |
Effect of dilutive stock-based compensation | ​ |  | ​ |  | ​ |  | ​
Stock options | 1,809 |  |  | — |  |  | 2,367 |  |  | — |
Restricted stock | 551 |  |  | — |  |  | 325 |  |  | — |
Total average equivalent shares | 66,922 |  |  | 64,562 |  |  | 66,702 |  |  | 64,010 |
Net income per share | $ | 0.95 |  |  | $ | 0.99 |  |  | $ | 0.85 |  |  | $ | 0.89 |

​

​ | Nine Months Ended
​ | September 30, 2020 |  | September 30, 2019
​ | Diluted |  | Basic |  | Diluted |  | Basic
Consolidated operations | ​ |  | ​ |  | ​ |  | ​
Income available to common stockholders | $ | 160,808 |  |  | $ | 160,808 |  |  | $ | 193,669 |  |  | $ | 193,669 |
​ | ​ |  | ​ |  | ​ |  | ​
Average equivalent shares | ​ |  | ​ |  | ​ |  | ​
Shares of common stock | 64,278 |  |  | 64,278 |  |  | 63,485 |  |  | 63,485 |
Effect of dilutive stock-based compensation | ​ |  | ​ |  | ​ |  | ​
Stock options | 1,770 |  |  | — |  | 2,425 |  |  | —
Restricted stock | 435 |  |  | — |  | 253 |  |  | —
Total average equivalent shares | 66,483 |  |  | 64,278 |  |  | 66,163 |  |  | 63,485 |
Net income per share | $ | 2.42 |  |  | $ | 2.50 |  |  | $ | 2.93 |  |  | $ | 3.05 |

​
​
​
NOTE 16 – SEGMENT INFORMATION
We are organized into three reporting segments. Our Beauty + Home segment sells to the personal care, beauty and home care markets. Our Pharma segment serves customers in the prescription drug, consumer health care, injectables and active packaging markets. Our Food + Beverage segment sells to the food and beverage markets.
The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2019. We evaluate performance of our business units and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives and acquisition-related costs. All internal segment reporting and discussions of results with our Chief Operating Decision Maker (CODM) are based on segment Adjusted EBITDA.
26

Table of Contents
Financial information regarding our reporting segments is shown below:

​ | Three Months Ended September 30, 2020 |  | Nine Months Ended September 30, 2020
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Total Sales: | ​ |  | ​ |  | ​ |  | ​
Beauty + Home | $ | 342,710 |  |  | $ | 333,870 |  |  | $ | 979,645 |  |  | $ | 1,056,626 |
Pharma | 317,610 |  |  | 271,608 |  |  | 921,085 |  |  | 830,679 |
Food + Beverage | 106,667 |  |  | 104,458 |  |  | 305,991 |  |  | 328,280 |
Total Sales | 766,987 |  |  | 709,936 |  |  | $ | 2,206,721 |  |  | $ | 2,215,585 |
Less: Intersegment Sales: | ​ |  | ​ |  | ​ |  | ​
Beauty + Home | $ | 5,479 |  |  | $ | 5,688 |  |  | $ | 18,068 |  |  | $ | 18,705 |
Pharma | 1,852 |  |  | 2,357 |  |  | 6,872 |  |  | 6,788 |
Food + Beverage | 503 |  |  | 613 |  |  | 1,770 |  |  | 1,693 |
Total Intersegment Sales | $ | 7,834 |  |  | $ | 8,658 |  |  | $ | 26,710 |  |  | $ | 27,186 |
Net Sales: | ​ |  | ​ |  | ​ |  | ​
Beauty + Home | $ | 337,231 |  |  | $ | 328,182 |  |  | $ | 961,577 |  |  | $ | 1,037,921 |
Pharma | 315,758 |  |  | 269,251 |  |  | 914,213 |  |  | 823,891 |
Food + Beverage | 106,164 |  |  | 103,845 |  |  | 304,221 |  |  | 326,587 |
Net Sales | $ | 759,153 |  |  | $ | 701,278 |  |  | $ | 2,180,011 |  |  | $ | 2,188,399 |
Adjusted EBITDA (1): | ​ |  | ​ |  | ​ |  | ​
Beauty + Home | $ | 34,733 |  |  | $ | 41,475 |  |  | $ | 92,954 |  |  | $ | 143,411 |
Pharma | 112,436 |  |  | 95,899 |  |  | 324,877 |  |  | 294,684 |
Food + Beverage | 20,351 |  |  | 18,728 |  |  | 53,543 |  |  | 56,363 |
Corporate & Other, unallocated | (10,964) |  |  | (9,943) |  |  | (34,071) |  |  | (33,328) |
Acquisition-related costs (2) | (221) |  |  | (708) |  |  | (6,087) |  |  | (1,767) |
Restructuring Initiatives (3) | (3,415) |  |  | (6,019) |  |  | (15,585) |  |  | (17,286) |
Depreciation and amortization | (55,179) |  |  | (49,218) |  |  | (162,414) |  |  | (144,574) |
Interest Expense | (8,851) |  |  | (8,898) |  |  | (25,973) |  |  | (26,868) |
Interest Income | 249 |  |  | 957 |  |  | 599 |  |  | 3,738 |
Income before Income Taxes | $ | 89,139 |  |  | $ | 82,273 |  |  | $ | 227,843 |  |  | $ | 274,373 |

________________________________________________
(1)We evaluate performance of our reporting segments and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives and acquisition-related costs.
(2)Acquisition-related costs include transaction costs and purchase accounting adjustments related to acquisitions and investments (see Note 17 – Acquisitions and Note 18 – Investment in Equity Securities for further details).
(3)Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2020 and 2019 as follows (see Note 19 – Restructuring Initiatives for further details):
​

​ | Three Months Ended September 30, 2020 |  | Nine Months Ended September 30, 2020
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Restructuring Initiatives by Segment | ​ |  | ​ |  | ​ |  | ​
Beauty + Home | $ | 3,144 |  |  | $ | 5,341 |  |  | $ | 15,375 |  |  | $ | 14,869 |
Pharma | 300 |  |  | 168 |  |  | 158 |  |  | 381 |
Food + Beverage | (31) |  |  | 204 |  |  | 147 |  |  | 826 |
Corporate & Other | 2 |  |  | 306 |  |  | (95) |  |  | 1,210 |
Total Restructuring Initiatives | $ | 3,415 |  |  | $ | 6,019 |  |  | $ | 15,585 |  |  | $ | 17,286 |

​
​
​
​
27

Table of Contents
NOTE 17 – ACQUISITIONS
Business Combinations
On April 1, 2020, we completed our acquisition (the “Fusion Acquisition”) of 100% of the equity interests of Fusion Packaging, Inc. (“Fusion”) for a purchase price of approximately $163.8 million (net of $1.0 million of cash acquired), which was funded by a draw on our revolving credit facility and cash on hand. Fusion, based in Dallas, TX, is a global leader in the design, engineering and distribution of luxury packaging for the beauty industry. As part of the Fusion Acquisition, we are also obligated to pay to the selling equity holders of Fusion certain contingent consideration based on 2022 cumulative financial performance metrics as defined in the purchase agreement. Based on a projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $19.1 million utilizing a Black-Scholes valuation model. As of September 30, 2020, we have estimated the aggregate fair value for this contingent consideration arrangement to be $22.1 million.
As of the acquisition date, $2.8 million was held in restricted cash pending the finalization of a working capital adjustment and indemnity escrow. During the third quarter of 2020, $2.0 million related to the working capital escrow was released from restriction, resulting in a refund from seller of $294 thousand and a corresponding decrease to our purchase price and associated goodwill balance. Fusion contributed net sales of $37.9 million and pretax loss of $1.5 million since acquisition for the period ended September 30, 2020 which have been included in the Condensed Consolidated Financial Statements within our Beauty + Home segment. Included in pretax loss is $5.7 million of fair value adjustment amortization for inventory sold during 2020 and contingent consideration liability adjustments.
On October 31, 2019, we completed our acquisition (the “Noble Acquisition”) of 100% of the equity interests of Noble International Holdings, Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as “Noble”). Noble, based in Orlando, FL, is a leading provider in developing patient-centric advanced drug delivery system training devices including autoinjector, prefilled syringe, onbody and respiratory devices for the world’s leading biopharmaceutical companies and original equipment manufacturers. The purchase price was approximately $62.3 million (net of $1.6 million of cash acquired) and was funded by cash on hand. As part of the Noble Acquisition, we are also obligated to pay to the selling equity holders of Noble certain contingent consideration based on 2024 cumulative financial performance metrics defined in the purchase agreement. Based on projection as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $2.9 million utilizing the Black-Scholes valuation model. As of September 30, 2020, we have estimated the aggregate fair value for this contingent consideration arrangement to be $4.2 million.
As of December 31, 2019, $5 million was held in restricted cash pending the finalization of a working capital adjustment and indemnity escrow. During the first quarter of 2020, $1.0 million related to the working capital escrow was released from restriction, resulting in an additional $463 thousand payment due to the seller and a corresponding increase to our purchase price and associated goodwill balance. The results of Noble’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.
On June 5, 2019, we completed our acquisition (the “Nanopharm Acquisition”) of all of the outstanding capital stock of Nanopharm Ltd. (“Nanopharm”). Nanopharm, located in Newport, UK, is a science-driven, leading provider of orally inhaled and nasal drug product design and development services. The purchase price was approximately $38.1 million (net of $1.8 million of cash acquired) and was funded by cash on hand. The results of Nanopharm’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.
On May 31, 2019, we completed our acquisition (the “Gateway Acquisition”) of all of the outstanding equity interests of Gateway Analytical LLC (“Gateway”). Gateway, located in Gibsonia, PA, provides industry-leading particulate detection and predictive analytical services to customers developing injectable medicines. The purchase price was approximately $7.0 million and was funded by cash on hand. As part of the Gateway Acquisition, we are also obligated to pay to the selling equity holder of Gateway certain contingent consideration based on 2020 and 2022 performance targets defined in the purchase agreement. Based on projections as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $3.0 million. During the second quarter 2020, $1.5 million of the contingent consideration accrual was paid as a result of the business meeting their first performance target. During the third quarter 2020, an additional $1.3 million was paid out in full satisfaction of the remaining earn out consideration and a gain of $235 thousand was realized. The results of Gateway’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.
28

Table of Contents
The following table summarizes the assets acquired and liabilities assumed as of the acquisition date at estimated fair value.

​ | 2020 |  | 2019
Assets | ​ |  | ​
Cash and equivalents | $ | 1,010 |  |  | $ | 3,427 |
Accounts receivable | 4,380 |  |  | 3,504 |
Inventories | 386 |  |  | — |
Prepaid and other | 1,090 |  |  | 2,478 |
Property, plant and equipment | 2,885 |  |  | 4,267 |
Goodwill | 99,644 |  |  | 59,143 |
Intangible assets | 79,900 |  |  | 52,980 |
Operating lease right-of-use assets | 4,744 |  |  | — |
Other miscellaneous assets | 65 |  |  | 430 |
Liabilities | ​ |  | ​
Accounts payable, accrued and other liabilities | 5,641 |  |  | 5,388 |
Deferred income taxes | — |  |  | 2,592 |
Operating lease liabilities | 4,207 |  |  | — |
Deferred and other non-current liabilities | 322 |  |  | 1,598 |
Net assets acquired | $ | 183,934 |  |  | $ | 116,651 |

​
The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date:

​ | 2020 |  | 2019
​ | Weighted-Average Useful Life (in Years) |  | Estimated Fair Value of Assets |  | Weighted-Average Useful Life (in Years) |  | Estimated Fair Value of Assets
Acquired technology | 4 |  | $ | 4,600 |  |  | 8 |  | $ | 9,160 |
Customer relationships | 13 |  | 62,300 |  |  | 11 |  | 39,379 |
Trademarks and trade names | 4 |  | 10,300 |  |  | 4 |  | 2,457 |
License agreements and other | 0.25 |  | 2,700 |  |  | 1 |  | 1,984 |
Total | ​ |  | $ | 79,900 |  |  | ​ |  | $ | 52,980 |

​
Goodwill in the amount of $99.6 million was recorded related to the Fusion Acquisition which is included in the Beauty + Home segment and $59.1 million was recorded related to the 2019 acquisitions, all of which are included in the Pharma segment. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill largely consists of unique relationships, brand equity and proprietary technology that has been established creating niches such as turnkey solutions for the beauty market related to the Fusion Acquisition, analytical services for drug developers related to the Nanopharm Acquisition and Gateway Acquisition and patient onboarding related to the Noble Acquisition, as well as the abilities of the acquired companies to maintain their competitive advantage from a technical viewpoint. Goodwill will not be amortized, but will be tested for impairment at least annually. For the Fusion Acquisition, goodwill of $82.3 million will be deductible for tax purposes. For the 2019 acquisitions, goodwill of $31.1 million will be deductible for tax purposes.
The unaudited pro forma results presented below include the effects of the Fusion Acquisition as if it had occurred as of January 1, 2019. The unaudited pro forma results reflect certain adjustments related to the acquisition, such as intangible asset amortization, fair value adjustments for inventory and financing costs related to the change in our debt structure. The pro forma results do not include any synergies or other expected benefits of the acquisition. Accordingly, the unaudited pro forma financial information below is not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been completed on the date indicated.
​
29

Table of Contents

​ | Three Months Ended September 30, 2020 |  | Nine Months Ended September 30, 2020
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Net Sales | $ | 759,153 |  |  | $ | 719,008 |  |  | $ | 2,187,974 |  |  | $ | 2,244,834 |
Net Income Attributable to AptarGroup Inc. | 63,724 |  |  | 57,191 |  |  | 160,077 |  |  | 196,195 |
Net Income per common share — basic | 0.99 |  |  | 0.89 |  |  | 2.49 |  |  | 3.09 |
Net Income per common share — diluted | 0.95 |  |  | 0.86 |  |  | 2.41 |  |  | 2.97 |

​
Asset Acquisition
On August 2, 2019, we completed our asset acquisition (the “Bapco Acquisition”) of the remaining 80% ownership interest in the capital stock of Bapco Closures Holdings Limited (“Bapco”), for $3.8 million (net of $2.9 million of cash acquired). The 20% ownership investment previously held in Bapco is now included within the intangible assets acquired. Bapco, located in Leeds, UK, provides innovative closures sealing technology that provides package integrity and tamper evidence. The results of Bapco’s operations have been included in the Condensed Consolidated Financial Statements within our Food + Beverage segment since the date of acquisition.
NOTE 18 – INVESTMENT IN EQUITY SECURITIES
Our investment in equity securities consisted of the following:​

​ | September 30, 2020 |  | December 31, 2019
Equity Method Investments: | ​ |  | ​
BTY | $ | 31,921 |  |  | $ | 119 |
Sonmol | 5,195 |  |  | — |
Kali Care | 3,611 |  |  | 3,881 |
Desotec GmbH | 904 |  |  | 858 |
​ |  |  |
Other Investments | 5,365 |  |  | 3,538 |
​ | $ | 46,995 |  |  | $ | 8,396 |

​
Equity method investments
Sonmol
On April 1, 2020, we invested $5 million to acquire 30% of the equity interests in Healthcare, Inc., Shanghai Sonmol Internet Technology Co., Ltd. and its subsidiary, Shanghai Sonmol Medical Equipment Co., Ltd. (collectively referred to as “Sonmol”), a pharmaceutical and leading Chinese digital respiratory therapeutics company that provides connected devices for asthma control and develops digital therapies and services platforms targeting chronic respiratory illnesses and other diseases.
BTY
On January 1, 2020, we acquired 49% of the equity interests in 3 related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY (collectively referred to as “BTY”) for an approximate purchase price of $32 million. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years subsequent to the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry.
Kali Care
During 2017, we invested $5 million to acquire 20% of the equity interests in Kali Care, a technology company that provides digital monitoring systems for medical devices.
30

Table of Contents
Desotec GmbH
During 2009, we invested €574 thousand to acquire 23% of the equity interests in Desotec GmbH, a leading manufacturer of special assembly machines for bulk processing for the pharmaceutical, beauty and home and food and beverages markets.
Other investments
During August 2019, we invested an aggregate amount of $3.5 million in two preferred equity investments in sustainability companies Loop and Purecycle Technologies (“Purecycle”) that are accounted for at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. In July and September 2020, we invested an additional $1.3 million in these two equity investments and also received $333 thousand of equity in Purecycle in exchange for our resource dedication for technological partnership and support.
There were no indications of impairment nor were there any changes from observable price changes noted in the nine months ended September 30, 2020 related to these investments.
​
NOTE 19 – RESTRUCTURING INITIATIVES
In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. For the three and nine months ended September 30, 2020, we recognized $3.4 million and $15.6 million of restructuring costs related to this plan, respectively. For the three and nine months ended September 30, 2019, we recognized $6.0 million and $17.3 million of restructuring costs related to this plan, respectively. Using current exchange rates, we estimate total implementation costs of approximately $125 million for these initiatives, including costs that have been recognized to date. The cumulative expense incurred as of September 30, 2020 was $102.1 million. We also anticipate making capital investments related to the transformation plan of approximately $50 million, of which $47 million has been incurred to date.
As of September 30, 2020 we have recorded the following activity associated with the business transformation:

​ | Beginning Reserve at 12/31/2019 |  | Net Charges for the Nine Months Ended 9/30/2020 |  | Cash Paid |  | Interest and FX Impact |  | Ending Reserve at 9/30/2020
Employee severance | $ | 7,090 |  |  | $ | 10,210 |  |  | $ | (6,157) |  |  | $ | 161 |  |  | $ | 11,304 |
Professional fees and other costs | 3,609 |  |  | 5,375 |  |  | (5,359) |  |  | 4 |  |  | 3,629 |
Totals | $ | 10,699 |  |  | $ | 15,585 |  |  | $ | (11,516) |  |  | $ | 165 |  |  | $ | 14,933 |

​
​
31

Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR AS OTHERWISE INDICATED)
​
RESULTS OF OPERATIONS
​

​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
​ | ​ |  | ​ |  | ​ |  | ​
Net sales | 100.0 | % |  | 100.0 | % |  | 100.0 | % |  | 100.0 | %
Cost of sales (exclusive of depreciation and amortization shown below) | 63.2 |  |  | 63.3 |  |  | 63.0 |  |  | 63.2 |
Selling, research & development and administrative | 16.1 |  |  | 15.9 |  |  | 17.0 |  |  | 15.8 |
Depreciation and amortization | 7.3 |  |  | 7.0 |  |  | 7.5 |  |  | 6.6 |
Restructuring initiatives | 0.4 |  |  | 0.9 |  |  | 0.7 |  |  | 0.8 |
Operating income | 13.0 |  |  | 12.9 |  |  | 11.8 |  |  | 13.6 |
Other expense | (1.3) |  |  | (1.2) |  |  | (1.3) |  |  | (1.1) |
Income before income taxes | 11.7 |  |  | 11.7 |  |  | 10.5 |  |  | 12.5 |
Net Income | 8.4 |  |  | 8.1 |  |  | 7.4 |  |  | 8.9 |
Effective tax rate | 28.5 | % |  | 31.0 | % |  | 29.4 | % |  | 29.4 | %
Adjusted EBITDA margin (1) | 20.6 | % |  | 20.8 | % |  | 20.1 | % |  | 21.1 | %

________________________________________________
(1)Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP Measures".
​
SIGNIFICANT DEVELOPMENTS
During the third quarter of 2020, financial results and operations continued to be adversely impacted by the novel coronavirus (“COVID-19”) pandemic. The significance of the impacts to our segments during the third quarter and first nine months of 2020 are discussed herein and include, but are not limited to, the adverse impact on sales of our beauty products sold via duty free travel and retail stores and a reduction of our products used for on-the-go beverage applications. The extent to which the COVID-19 pandemic impacts our financial results and operations for fiscal year 2020 and going forward for all three of our business segments will depend on future developments which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the outbreak and the international actions being taken to contain and treat it. No impairments were recorded as of September 30, 2020. While the disruption is currently expected to be temporary, there is uncertainty around the duration and the extent of further resurgences. Due to significant uncertainty surrounding the situation, future results could change and therefore our results could be materially impacted.
As each of our segments produce dispensing systems that have been determined to be essential products by various government agencies around the world, our facilities remained operational during the third quarter of 2020. We have taken a variety of measures to ensure the availability and functioning of our critical infrastructure, to promote the safety and security of our employees and to support the communities in which we operate. These measures include requiring remote working arrangements for employees where practicable. We are following public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions, the promotion of social distancing and the adoption of work-from-home arrangements, and all of these policies and initiatives have impacted our operations. Due to the dynamic nature of the situation, we are not able at this time to estimate the impact of COVID-19 on our future financial results and operations, but the impact could be material for the remainder of fiscal year 2020 and could be material during any future periods affected either directly or indirectly by this pandemic. See Part II, Item 1A, “Risk Factors,” included in this report for information on material risks associated with COVID-19.
32

Table of Contents
NET SALES
We reported net sales of $759.2 million for the quarter ended September 30, 2020, which represents an 8% increase compared to $701.3 million reported during the third quarter of 2019. Reported sales were positively impacted by acquisitions and changes in currency exchange rates. The acquisitions of Noble and Fusion positively impacted sales by 4%. The average U.S. dollar exchange rate weakened compared to the euro while it appreciated against most Latin America and Asian currencies, resulting in a positive currency translation impact of 2%. Therefore, core sales, which exclude acquisitions and changes in foreign currency rates, increased by 2% in the third quarter of 2020 compared to the same period in 2019. During the third quarter of 2020, our Pharma segment experienced strong, broad-based demand with particularly strong growth in our injectables division and strong custom tooling and product sales in our active packaging division. While sales to our beauty markets continue to be negatively impacted by the effects of COVID-19, our Beauty + Home segment benefited from strong sales to the personal care market related to hand sanitizers and liquid soaps and the home care market related to cleaners and disinfectants. Our Food + Beverage segment reported positive sales growth with strong sales to the food market due to the demand for pantry staples with consumers continuing to cook at home during the pandemic. Sales to the beverage market continued to be impacted by lower demand for on-the-go beverages related to the pandemic.

Third Quarter 2020 Net Sales Change over Prior Year | Beauty + Home |  | Pharma |  | Food + Beverage |  | Total
Core Sales Growth | (5) | % |  | 11 | % |  | 2 | % |  | 2 | %
Acquisitions | 7 | % |  | 2 | % |  | — | % |  | 4 | %
Currency Effects (1) | 1 | % |  | 4 | % |  | — | % |  | 2 | %
Total Reported Net Sales Growth | 3 | % |  | 17 | % |  | 2 | % |  | 8 | %

​
For the first nine months of 2020, reported net sales of $2.18 billion, were in line with the first nine months of 2019 reported net sales of $2.19 billion. Sales were negatively impacted by changes in currency exchange rates, passing-through lower resin costs to customers and COVID-19 related effects on certain markets we serve. While the average U.S. dollar exchange rate did not change compared to the euro, it strengthened compared to most of the other major currencies we operate in, resulting in a negative currency translation impact of 1%. The acquisitions of Gateway, Nanopharm, Noble and Fusion positively impacted sales by 3%. Therefore, core sales, which exclude acquisitions and changes in foreign currency rates, decreased by 2% in the first nine months of 2020 compared to the same period in 2019. As discussed above, both our Beauty + Home and Food + Beverage segments have been significantly impacted by the COVID-19 pandemic, along with a negative impact of passing through lower resin costs to our customers.

Nine Months Ended September 30, 2020 Net Sales Change over Prior Year | Beauty + Home |  | Pharma |  | Food + Beverage |  | Total
Core Sales Growth | (9) | % |  | 8 | % |  | (5) | % |  | (2) | %
Acquisitions | 4 | % |  | 3 | % |  | — | % |  | 3 | %
Currency Effects (1) | (2) | % |  | — | % |  | (2) | % |  | (1) | %
Total Reported Net Sales Growth | (7) | % |  | 11 | % |  | (7) | % |  | — | %

________________________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
The following table sets forth, for the periods indicated, net sales by geographic location:
​

​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | % of Total |  | 2019 |  | % of Total |  | 2020 |  | % of Total |  | 2019 |  | % of Total
Domestic | $ | 262,546 |  |  | 35 | % |  | $ | 211,497 |  |  | 30 | % |  | $ | 722,871 |  |  | 33 | % |  | $ | 640,543 |  |  | 29 | %
Europe | 401,765 |  |  | 53 | % |  | 391,512 |  |  | 56 | % |  | 1,189,680 |  |  | 55 | % |  | 1,248,411 |  |  | 57 | %
Latin America | 49,435 |  |  | 6 | % |  | 54,685 |  |  | 8 | % |  | 143,598 |  |  | 6 | % |  | 170,605 |  |  | 8 | %
Asia | 45,407 |  |  | 6 | % |  | 43,584 |  |  | 6 | % |  | 123,862 |  |  | 6 | % |  | 128,840 |  |  | 6 | %

​
For further discussion on net sales by reporting segment, please refer to the analysis of segment net sales and segment Adjusted EBITDA on the following pages.
33

Table of Contents
COST OF SALES (EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW)
Cost of sales (“COS”) as a percent of net sales remained consistent at 63.2% in the third quarter of 2020 compared to 63.3% in the third quarter of 2019. Our COS percentage was positively impacted by our cost containment efforts and the mix of business as we reported sales growth in our higher margin Pharma segment. We also benefited from lower resin costs during the quarter as resin prices have declined compared to the prior year. However, we did experience some additional costs and under-absorbed overhead primarily in our dedicated beauty facilities during the third quarter of 2020 related to the COVID-19 pandemic.
Cost of sales as a percent of net sales decreased slightly to 63.0% in the first nine months of 2020 compared to 63.2% in the same period a year ago. As mentioned above, our COS was favorably impacted by the increased mix in our higher margin Pharma business, lower resin costs and cost containment efforts. However, we also reported additional costs and temporary inefficiencies in our manufacturing process related to the COVID-19 pandemic as discussed above. For example, we declared special bonus payments to certain employees who worked to maintain supply to our customers and keep our facilities running, which increased our COS percentage during the first nine months of 2020.
SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE
Selling, research & development and administrative expenses (“SG&A”) increased by approximately $10.3 million to $121.9 million in the third quarter of 2020 compared to $111.6 million during the same period in 2019. Excluding changes in foreign currency rates, SG&A increased by approximately $8.6 million in the quarter. The increase is mainly due to $6.9 million of new operational costs for our acquisitions completed subsequent to September 30, 2019, as well as fair value adjustments related to contingent consideration arrangements. We also recognized higher personnel costs, including $3.5 million of stock-based compensation mainly for our acquired entities which was offset by lower travel costs due to the COVID-19 pandemic. SG&A as a percentage of net sales increased to 16.1% compared to 15.9% in the same period of the prior year due to the cost increases mentioned above.
SG&A increased by $24.9 million to $371.4 million in the first nine months of 2020 compared to $346.5 million during the same period a year ago. Excluding changes in foreign currency rates, SG&A increased by approximately $28.7 million in the first nine months of 2020 compared to the first nine months of 2019. As discussed above, the increase is related to $15.7 million of new SG&A costs from our acquisitions completed subsequent to September 30, 2019 as well as fair value adjustments related to contingent consideration arrangements, along with higher personnel costs. SG&A as a percentage of net sales increased to 17.0% compared to 15.8% in the same period of the prior year due to the cost increases mentioned above.
DEPRECIATION AND AMORTIZATION
Reported depreciation and amortization expenses increased by approximately $6.0 million to $55.2 million in the third quarter of 2020 compared to $49.2 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $5.1 million in the quarter compared to the same period in 2019. The majority of this increase is due to $3.3 million of incremental depreciation and amortization costs related to our acquired companies. Depreciation and amortization as a percentage of net sales increased to 7.3% in the third quarter of 2020 compared to 7.0% in the same period of the prior year.
Reported depreciation and amortization expenses increased by approximately $17.8 million to $162.4 million in the first nine months of 2020 compared to $144.6 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $19.3 million in the first nine months of 2020 compared to the same period a year ago. The majority of this increase is due to $11.7 million of incremental depreciation and amortization costs related to our acquired companies. Depreciation and amortization as a percentage of net sales increased to 7.5% in the first nine months of 2020 compared to 6.6% in the same period of the prior year.
34

Table of Contents
RESTRUCTURING INITIATIVES
In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. Restructuring costs related to this plan for the three and nine months ended September 30, 2020 and 2019 are as follows:

​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Restructuring Initiatives by Segment | ​ |  | ​ |  | ​ |  | ​
Beauty + Home | $ | 3,144 |  |  | $ | 5,341 |  |  | $ | 15,375 |  |  | $ | 14,869 |
Pharma | 300 |  |  | 168 |  |  | 158 |  |  | 381 |
Food + Beverage | (31) |  |  | 204 |  |  | 147 |  |  | 826 |
Corporate & Other | 2 |  |  | 306 |  |  | (95) |  |  | 1,210 |
Total Restructuring Initiatives | $ | 3,415 |  |  | $ | 6,019 |  |  | $ | 15,585 |  |  | $ | 17,286 |

​
We estimate total implementation costs of approximately $125 million, including $102.1 million of costs that have been recognized to date. We also anticipate making capital investments related to the business transformation of approximately $50 million, of which $47 million has been incurred to date. Based on our ongoing restructuring initiatives, we are progressing towards our initial target of $80 million annualized incremental EBITDA by the end of 2020, principally within the Beauty + Home segment. However, in addition to the impacts of COVID-19, ongoing changes in customer and vendor negotiations, material indices, macro-economic trends and other factors represent continuing headwinds to the Beauty + Home segment, and have offset the consolidated net benefits from these initiatives.
OPERATING INCOME
Operating income increased approximately $8.8 million to $99.0 million in the third quarter of 2020 compared to $90.2 million in the same period a year ago. Excluding changes in foreign currency rates, operating income increased by approximately $5.0 million in the quarter compared to the same period a year ago. This increase is due to higher sales volumes while maintaining a consistent gross margin. We also benefited from lower restructuring costs during the third quarter of 2020 compared to the prior year period. Operating income as a percentage of net sales increased slightly to 13.0% in the third quarter of 2020 compared to 12.9% in the prior year period.
For the first nine months of 2020, operating income decreased approximately $39.2 million to $258.0 million compared to $297.2 million in the same period of the prior year. Excluding changes in foreign currency rates, operating income decreased by approximately $38.8 million in the first nine months of 2020 compared to the same period a year ago. The majority of this decrease occurred during the second quarter of 2020 due to the impact of lower sales and operational inefficiencies related to the COVID-19 pandemic. Operating income as a percentage of net sales decreased to 11.8% in the first nine months of 2020 compared to 13.6% for the same period in the prior year.
NET OTHER EXPENSE
Net other expense in the third quarter of 2020 increased $1.9 million to $9.9 million from $8.0 million in the same period of the prior year. Interest income decreased by approximately $0.7 million due to less cash on hand after our acquisition of Fusion at the beginning of the second quarter 2020. Miscellaneous expenses increased by approximately $0.8 million as a result of higher pension costs due to the decline in discount rates in 2020 compared to 2019 and higher costs to hedge certain Latin American currencies.
Net other expense for the nine months ended September 30, 2020 increased $7.3 million to $30.1 million from $22.8 million in the same period of the prior year. As discussed above, this increase is mainly due to $3.1 million of lower interest income in 2020 as a result of the Fusion Acquisition. Miscellaneous expenses increased by approximately $3.5 million mainly due to the higher pension costs and higher costs to hedge certain Latin American currencies as mentioned above.
EFFECTIVE TAX RATE
The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings and related estimated full year-taxes, adjusted for the impact of discrete quarterly items.
The effective tax rate for the three months ended September 30, 2020 and 2019, respectively, was 28.5% and 31.0%. The reported effective tax rate for the three months ended September 30, 2020 was favorably impacted by additional excess tax benefits from employee stock-based compensation of $1.4 million and benefits reflecting changes in the U.S. GILTI tax for the current year of $1.5 million.
35

Table of Contents
The effective tax rate for the nine months ended September 30, 2020 and 2019 was 29.4%. The nine month effective tax rates reflect a favorable impact from the excess tax benefits from employee stock-based compensation of $8.7 million and $13.6 million, respectively, offset by the unfavorable impact from losses in jurisdictions where the tax benefit is not recognized and other discrete items of $5.1 million and $10.9 million, respectively.
​
NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.
We reported net income attributable to AptarGroup of $63.7 million and $160.8 million in the three and nine months ended September 30, 2020, compared to $56.8 million and $193.7 million for the same periods in the prior year.
BEAUTY + HOME SEGMENT
Operations that sell dispensing systems and sealing solutions to the personal care, beauty and home care markets form the Beauty + Home segment.
​

​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Net Sales | $ | 337,231 |  |  | $ | 328,182 |  |  | $ | 961,577 |  |  | $ | 1,037,921 |
Adjusted EBITDA (1) | 34,733 |  |  | 41,475 |  |  | 92,954 |  |  | 143,411 |
Adjusted EBITDA margin (1) | 10.3 | % |  | 12.6 | % |  | 9.7 | % |  | 13.8 | %

________________________________________________
(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP Measures".
Reported net sales for the quarter ended September 30, 2020 increased 3% to $337.2 million compared to $328.2 million in the third quarter of the prior year. Changes in currency rates positively impacted net sales by 1% while our acquisition of Fusion contributed an additional 7% to the top line growth in the third quarter of 2020. Therefore, core sales decreased 5% in the third quarter of 2020 compared to the same quarter of the prior year. The COVID-19 pandemic continued to negatively impact core sales to the beauty market during the third quarter of 2020 due to significant reduction in domestic and international travel leading to a reduction in duty free sales. Core sales of our products to the beauty market decreased 21% as we continued to experience a significant reduction in orders from customers providing both fragrance and skin care products, mainly in the travel retail and standard retail settings. Personal care core sales increased 12% on increased sales of our products to our personal cleansing customers, mainly for hand sanitizers and liquid soaps which more than compensated for continued softness in our deodorant, hair care and sun care applications as consumers continued to shelter in place. Core sales to the home care markets increased 6% on strong demand for our household cleaner and disinfectant products.

Third Quarter 2020 Net Sales Change over Prior Year | Personal Care |  | Beauty |  | Home Care |  | Total
Core Sales Growth | 12 | % |  | (21) | % |  | 6 | % |  | (5) | %
Acquisitions | — | % |  | 14 | % |  | — | % |  | 7 | %
Currency Effects (1) | — | % |  | 1 | % |  | 1 | % |  | 1 | %
Total Reported Net Sales Growth | 12 | % |  | (6) | % |  | 7 | % |  | 3 | %

​
For the first nine months of 2020, net sales decreased 7% to $0.96 billion compared to $1.04 billion in the first nine months of the prior year. Changes in currency rates negatively impacted net sales by 2% while our acquisition of Fusion positively impacted sales by 4% in the first nine months of 2020. Therefore, core sales decreased by 9% in the first nine months of 2020 compared to the same period in the prior year. The COVID-19 pandemic also impacted the first nine months of 2020 as we began to see the effects in our first quarter results. Core sales of our products to the beauty market decreased 22% across all applications, but mainly on lower sales of prestige fragrance products to our customers. Compared to the same period in the prior year, personal care core sales increased 6%, driven by increases in hand sanitation product sales, while home care core sales decreased 2% mainly on lower sales to our laundry care customers.
36

Table of Contents

Nine Months Ended September 30, 2020 Net Sales Change over Prior Year | Personal Care |  | Beauty |  | Home Care |  | Total
Core Sales Growth | 6 | % |  | (22) | % |  | (2) | % |  | (9) | %
Acquisitions | — | % |  | 7 | % |  | — | % |  | 4 | %
Currency Effects (1) | (2) | % |  | (2) | % |  | (1) | % |  | (2) | %
Total Reported Net Sales Growth | 4 | % |  | (17) | % |  | (3) | % |  | (7) | %

________________________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
Adjusted EBITDA in the third quarter of 2020 decreased 16% to $34.7 million compared to $41.5 million in the same period in the prior year. As discussed above, the COVID-19 pandemic affected our profitability due to overall lower sales volumes. Our profitability was further impacted by lower overhead absorption due to fluctuations in demand primarily in our facilities that manufacture beauty products. We also incurred $1.8 million of fair value adjustments related to our contingent consideration arrangement for the Fusion Acquisition.
Adjusted EBITDA in the first nine months of 2020 decreased 35% to $93.0 million compared to $143.4 million reported in the same period in the prior year. As discussed above, our profitability during the first nine months of 2020 was significantly impacted by the COVID-19 pandemic, mainly in our beauty applications. Our profitability was further impacted by special employee bonus payments to certain employees who worked to maintain supply to our customers and keep our facilities running as well as lower overhead absorption as we continue to manage demand fluctuations in our facilities. We also incurred $3.0 million of fair value adjustments related to our contingent consideration arrangement for the Fusion Acquisition.
PHARMA SEGMENT
Operations that sell drug delivery, sealing and active packaging solutions primarily to the prescription drug, consumer health care, injectables and active packaging markets form the Pharma segment.
​

​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Net Sales | $ | 315,758 |  |  | $ | 269,251 |  |  | $ | 914,213 |  |  | $ | 823,891 |
Adjusted EBITDA (1) | 112,436 |  |  | 95,899 |  |  | 324,877 |  |  | 294,684 |
Adjusted EBITDA margin (1) | 35.6 | % |  | 35.6 | % |  | 35.5 | % |  | 35.8 | %

________________________________________________
(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP Measures".
Net sales for the Pharma segment increased 17% in the third quarter of 2020 to $315.8 million compared to $269.3 million in the third quarter of 2019. Changes in currencies positively affected net sales by 4% while our acquisition of Noble positively impacted sales by 2% in the third quarter of 2020. Therefore, core sales increased by 11% in the third quarter of 2020 compared to the third quarter of 2019. Core sales increased in each end market with the exception of the prescription drug market where higher sales of drug delivery devices were offset by lower custom tooling sales. Core sales to the consumer health care market increased 6% on strong demand for our products used on nasal saline and nasal decongestant treatments. Injectables core sales increased 27% on higher demand for primary components used with injected medicines such as existing seasonal flu vaccines and other treatments, as well as some initial orders in anticipation of coming COVID-19 vaccines. Active packaging core sales increased 56% mainly due to two large tooling projects during the quarter. We also reported strong sales growth in our ActivVial and ActivFilm used with probiotic and oral solid dose products.

Third Quarter 2020 Net Sales Change over Prior Year | Prescription Drug |  | Consumer Health Care |  | Injectables |  | Active Packaging |  | Total
Core Sales Growth | — | % |  | 6 | % |  | 27 | % |  | 56 | % |  | 11 | %
Acquisitions | — | % |  | — | % |  | 14 | % |  | — | % |  | 2 | %
Currency Effects (1) | 3 | % |  | 5 | % |  | 6 | % |  | 3 | % |  | 4 | %
Total Reported Net Sales Growth | 3 | % |  | 11 | % |  | 47 | % |  | 59 | % |  | 17 | %

​
37

Table of Contents
Net sales for the first nine months of 2020 increased by 11% to $914.2 million compared to $823.9 million in the first nine months of 2019. While there was no impact from changes in currencies, our acquisitions of Noble, Nanopharm and Gateway positively impacted sales by 3% in the first nine months of 2020. Therefore, core sales increased by 8% in the first nine months of 2020 compared to the same period in the prior year. The core sales decrease of 1% in the prescription drug market was driven by difficult prior year comparisons on tooling and central nervous system application sales. During 2019, we also benefited from the realization of $1.8 million of revenue for achieving a development milestone related to a customer project. Core sales to the consumer health care market increased 6% on strong demand for our products used on nasal decongestant, cough and cold and dermal drug delivery treatments. Core sales of our products to the injectables and active packaging markets increased 25% and 34% respectively due to strong sales across all applications and tooling as discussed above.
​

Nine Months Ended September 30, 2020 Net Sales Change over Prior Year | Prescription Drug |  | Consumer Health Care |  | Injectables |  | Active Packaging |  | Total
Core Sales Growth | (1) | % |  | 6 | % |  | 25 | % |  | 34 | % |  | 8 | %
Acquisitions | — | % |  | — | % |  | 16 | % |  | — | % |  | 3 | %
Currency Effects (1) | — | % |  | 1 | % |  | — | % |  | — | % |  | — | %
Total Reported Net Sales Growth | (1) | % |  | 7 | % |  | 41 | % |  | 34 | % |  | 11 | %

_______________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
Adjusted EBITDA in the third quarter of 2020 increased 17% to $112.4 million compared to $95.9 million reported in the same period of the prior year. As discussed above, we reported strong product growth across most markets and benefited from higher tooling sales within our active packaging market. These core sales improvements, along with strong performance resulting from the Noble Acquisition led to the increase in reported results for the third quarter of 2020 compared to the third quarter of 2019. These improvements were slightly offset by $0.9 million higher stock-based compensation expense and $1.3 million of fair value adjustments related to our contingent consideration arrangement for the Noble Acquisition.
Adjusted EBITDA in the first nine months of 2020 increased 10% to $324.9 million compared to $294.7 million reported in the same period of the prior year. Increased sales in three of our divisions, along with incremental profit related to our acquisitions was able to compensate for $2.6 million of additional stock-based compensation expense and $1.3 million of fair value adjustments related to our contingent consideration arrangement for the Noble Acquisition. While the Pharma segment did not experience a significant sales impact from COVID-19, our margins were negatively impacted by lower sales of our high-margin prescription applications compared to our other product offerings. We also made special bonus payments to certain employees who worked to maintain supply to our customers and keep our facilities running.
​
FOOD + BEVERAGE SEGMENT
Operations that sell dispensing systems and sealing solutions to the food and beverage markets form the Food + Beverage segment.
​

​ | Three Months Ended September 30, |  | Nine Months Ended September 30,
​ | 2020 |  | 2019 |  | 2020 |  | 2019
Net Sales | $ | 106,164 |  |  | $ | 103,845 |  |  | $ | 304,221 |  |  | $ | 326,587 |
Adjusted EBITDA (1) | 20,351 |  |  | 18,728 |  |  | 53,543 |  |  | 56,363 |
Adjusted EBITDA margin (1) | 19.2 | % |  | 18.0 | % |  | 17.6 | % |  | 17.3 | %

________________________________________________
(1)Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring initiatives and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation under "Non-U.S. GAAP Measures".
Core sales for the quarter ended September 30, 2020 increased approximately 2% to $106.2 million compared to $103.8 million in the third quarter of the prior year. There were no acquisitions or changes in foreign currency rates during the third quarter of 2020 compared to the third quarter of 2019. Core sales growth was negatively impacted by $3.5 million from passing through lower resin costs to our customers. The changes in core sales by market show distinctly different results, but both are being impacted by the COVID-19 pandemic. Core sales to the food market increased 15% due to the increased demand across several applications for pantry staples as consumers continued to cook at home during the pandemic. However, core sales to the beverage market decreased 22% as sales of our single-serve bottled water and on-the-go functional drink products continue to be negatively impacted as consumers demand less on-the-go beverages during the COVID-19 pandemic.
38

Table of Contents

Third Quarter 2020 Net Sales Change over Prior Year | Food |  | Beverage |  | Total
Core Sales Growth | 15 | % |  | (22) | % |  | 2 | %
Acquisitions | — | % |  | — | % |  | — | %
Currency Effects (1) | — | % |  | (1) | % |  | — | %
Total Reported Net Sales Growth | 15 | % |  | (23) | % |  | 2 | %

​
Net sales for the first nine months of 2020 decreased by 7% to $304.2 million compared to $326.6 million in the first nine months of 2019. Changes in currency rates negatively impacted net sales by 2%. Therefore, core sales decreased by 5% in the first nine months of 2020 compared to the same period in the prior year. The pass-through of lower resin costs and lower tooling sales negatively impacted the first nine months of 2020 by $12.2 million and $6.4 million, respectively. Core sales to the food market increased 4% while core sales to the beverage market decreased 25% in the first nine months of 2020 compared to the same period of the prior year. Sales to the food market increased due to strong sales of our products to our spreads, cooking oils and granular/powder customers. These increases were offset by lower tooling sales versus the prior year period. As discussed above, core sales to the beverage market decreased as sales of our single-serve bottled water and on-the-go functional drink products as well as tooling sales were all significantly affected by the COVID-19 pandemic.

Nine Months Ended September 30, 2020 Net Sales Change over Prior Year | Food |  | Beverage |  | Total
Core Sales Growth | 4 | % |  | (25) | % |  | (5) | %
Acquisitions | — | % |  | — | % |  | — | %
Currency Effects (1) | (1) | % |  | (2) | % |  | (2) | %
Total Reported Net Sales Growth | 3 | % |  | (27) | % |  | (7) | %

______________________________________________________________
(1)Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.
Adjusted EBITDA in the third quarter of 2020 increased 9% to $20.4 million compared to $18.7 million reported in the same period of the prior year. Higher product sales to the food markets discussed above, along with the benefits we received from our cost containment activities and other operational improvements realized during the third quarter of 2020 more than compensated for lower tooling sales and other negative COVID-19 impacts, mainly on our beverage market applications.
Adjusted EBITDA in the first nine months of 2020 decreased 5% to $53.5 million compared to $56.4 million reported in the same period of the prior year. The COVID-19 impact on product sales discussed above, along with lower tooling and special bonus payments to certain employees who worked to maintain supply to our customers and keep our facilities running, more than offset the benefits we received from cost containment activities and other operational improvements realized during the first nine months of 2020.
​
CORPORATE & OTHER
In addition to our three reporting segments, we assign certain costs to “Corporate & Other,” which is presented separately in Note 16 – Segment Information to the Notes to the Condensed Consolidated Financial Statements. For Corporate & Other, Adjusted EBITDA (which excludes net interest, taxes, depreciation, amortization, restructuring initiatives and acquisition-related costs) primarily includes certain professional fees, compensation and information system costs which are not allocated directly to our reporting segments. For the quarter ended September 30, 2020, Corporate & Other expenses increased to $11.0 million from $9.9 million in the third quarter of 2019. Of the $1.1 million increase, $0.4 million is due to changes in foreign currencies. The remaining increase is due to slightly higher variable compensation costs which are tied to company performance and other personnel costs as we continue to implement our growth strategy partially offset by lower travel and entertainment costs due to travel restrictions in place during 2020 .
Corporate & Other expenses in the first nine months of 2020 increased to $34.1 million compared to $33.3 million reported in the same period of the prior year. Of the $0.8 million increase, $0.3 million is due to changes in foreign currencies. As discussed above, the remaining increase is due to higher variable compensation and other personnel costs partially offset by lower travel and entertainment costs.
39

Table of Contents
NON-U.S. GAAP MEASURES
In addition to the information presented herein that conforms to U.S. GAAP, we also present financial information that does not conform to U.S. GAAP, which are referred to as non-U.S. GAAP financial measures. Management may assess our financial results both on a U.S. GAAP basis and on a non-U.S. GAAP basis. We believe it is useful to present these non-U.S. GAAP financial measures because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect our core operating performance. These non-U.S. GAAP financial measures should not be considered in isolation or as a substitute for U.S. GAAP financial results, but should be read in conjunction with the unaudited Condensed Consolidated Statements of Income and other information presented herein. Investors are cautioned against placing undue reliance on these non-U.S. GAAP measures. Further, investors are urged to review and consider carefully the adjustments made by management to the most directly comparable U.S. GAAP financial measure to arrive at these non-U.S. GAAP financial measures.
In our Management’s Discussion and Analysis, we exclude the impact of foreign currency translation when presenting net sales information, which we define as “constant currency.” Changes in net sales excluding the impact of foreign currency translation is a non-U.S. GAAP financial measure. As a worldwide business, it is important that we take into account the effects of foreign currency translation when we view our results and plan our strategies. Consequently, when our management looks at our financial results to measure the core performance of our business, we may exclude the impact of foreign currency translation by translating our prior period results at current period foreign currency exchange rates. As a result, our management believes that these presentations are useful internally and may be useful to investors. We also exclude the impact of material acquisitions when comparing results to prior periods. Changes in operating results excluding the impact of acquisitions are non-U.S. GAAP financial measures. We believe it is important to exclude the impact of acquisitions on period over period results in order to evaluate performance on a more comparable basis.
We present adjusted earnings before net interest and taxes (“Adjusted EBIT”) and consolidated adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”), both of which exclude the business transformation charges (restructuring initiatives), acquisition-related costs and purchase accounting adjustments related to acquisitions and investments. Our “Outlook” discussion below is also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives and acquisition-related costs.
We provide a reconciliation of Net Debt to Net Capital as a non-U.S. GAAP measure. “Net Debt” is calculated as interest bearing debt less cash and equivalents and short-term investments while “Net Capital” is calculated as stockholders’ equity plus Net Debt. Net Debt to Net Capital measures a company’s financial leverage, which gives users an idea of a company's financial structure, or how it is financing its operations, along with insight into its financial strength. We believe that it is meaningful to take into consideration the balance of our cash and equivalents, and short-term investments when evaluating our leverage. If needed, such assets could be used to reduce our gross debt position.
Finally, we provide a reconciliation of free cash flow as a non-U.S. GAAP measure. Free cash flow is calculated as cash provided by operations less capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives.
40

Table of Contents

​ | Three Months Ended
​ | September 30, 2020
​ | ​ |  |
​ | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | $ | 759,153 |  |  | $ | 337,231 |  |  | $ | 315,758 |  |  | $ | 106,164 |  |  | $ | — |  |  | $ | — |
​ |  |  |  |  |  |  |  |  |  |  |
Reported net income | $ | 63,735 |  |  |  |  |  |  |  |  |  |  |
Reported income taxes | 25,404 |  |  |  |  |  |  |  |  |  |  |
Reported income before income taxes | 89,139 |  |  | 7,944 |  |  | 92,202 |  |  | 10,884 |  |  | (13,289) |  |  | (8,602) |
Adjustments: |  |  |  |  |  |  |  |  |  |  |
Restructuring initiatives | 3,415 |  |  | 3,144 |  |  | 300 |  |  | (31) |  |  | 2 |  |  |
Transaction costs related to acquisitions | 221 |  |  | 11 |  |  | 210 |  |  |  |  |  |  |
Adjusted earnings before income taxes | 92,775 |  |  | 11,099 |  |  | 92,712 |  |  | 10,853 |  |  | (13,287) |  |  | (8,602) |
Interest expense | 8,851 |  |  |  |  |  |  |  |  |  |  | 8,851 |
Interest income | (249) |  |  |  |  |  |  |  |  |  |  | (249) |
Adjusted earnings before net interest and taxes (Adjusted EBIT) | 101,377 |  |  | 11,099 |  |  | 92,712 |  |  | 10,853 |  |  | (13,287) |  |  | — |
Depreciation and amortization | 55,179 |  |  | 23,634 |  |  | 19,724 |  |  | 9,498 |  |  | 2,323 |  |  |
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | $ | 156,556 |  |  | $ | 34,733 |  |  | $ | 112,436 |  |  | $ | 20,351 |  |  | $ | (10,964) |  |  | $ | — |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | 20.6 | % |  | 10.3 | % |  | 35.6 | % |  | 19.2 | % |  | ​ |  | ​

41

Table of Contents

​ | Three Months Ended
​ | September 30, 2019
​ | ​ |
​ | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | $ | 701,278 |  |  | $ | 328,182 |  |  | $ | 269,251 |  |  | $ | 103,845 |  |  | $ | — |  |  | $ | — |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Reported net income | $ | 56,769 |  |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Reported income taxes | 25,504 |  |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Reported income before income taxes | 82,273 |  |  | 15,413 |  |  | 78,418 |  |  | 9,323 |  |  | (12,940) |  |  | (7,941) |
Adjustments: | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Restructuring initiatives | 6,019 |  |  | 5,341 |  |  | 168 |  |  | 204 |  |  | 306 |  |  | ​
Transaction costs related to acquisitions | 708 |  |  | 34 |  |  | 520 |  |  | 154 |  |  | ​ |  | ​
Purchase accounting adjustments related to acquisitions and investments | 647 |  |  | ​ |  | 647 |  |  | ​ |  | ​ |  | ​
Adjusted earnings before income taxes | 89,647 |  |  | 20,788 |  |  | 79,753 |  |  | 9,681 |  |  | (12,634) |  |  | (7,941) |
Interest expense | 8,898 |  |  | ​ |  | ​ |  | ​ |  | ​ |  | 8,898 |
Interest income | (957) |  |  | ​ |  | ​ |  | ​ |  | ​ |  | (957) |
Adjusted earnings before net interest and taxes (Adjusted EBIT) | 97,588 |  |  | 20,788 |  |  | 79,753 |  |  | 9,681 |  |  | (12,634) |  |  | — |
Depreciation and amortization | 49,218 |  |  | 20,687 |  |  | 16,793 |  |  | 9,047 |  |  | 2,691 |  |  | ​
Purchase accounting adjustments included in Depreciation and amortization above | (647) |  |  | ​ |  | (647) |  |  | ​ |  | ​ |  | — |
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | $ | 146,159 |  |  | $ | 41,475 |  |  | $ | 95,899 |  |  | $ | 18,728 |  |  | $ | (9,943) |  |  | $ | — |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | 20.8 | % |  | 12.6 | % |  | 35.6 | % |  | 18.0 | % |  | ​ |  | ​

​
42

Table of Contents

​ | Nine Months Ended
​ | September 30, 2020
​ | ​ |
​ | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | $ | 2,180,011 |  |  | $ | 961,577 |  |  | $ | 914,213 |  |  | $ | 304,221 |  |  | $ | — |  |  | $ | — |
​ |  |  |  |  |  |  |  |  |  |  |
Reported net income | $ | 160,845 |  |  |  |  |  |  |  |  |  |  |
Reported income taxes | 66,998 |  |  |  |  |  |  |  |  |  |  |
Reported income before income taxes | 227,843 |  |  | 2,297 |  |  | 267,523 |  |  | 25,365 |  |  | (41,968) |  |  | (25,374) |
Adjustments: |  |  |  |  |  |  |  |  |  |  |
Restructuring initiatives | 15,585 |  |  | 15,375 |  |  | 158 |  |  | 147 |  |  | (95) |  |  |
Transaction costs related to acquisitions | 4,812 |  |  | 4,602 |  |  | 210 |  |  |  |  |  |  |
Purchase accounting adjustments related to acquisitions and investments | 4,642 |  |  | 3,221 |  |  | 1,421 |  |  |  |  |  |  |
Adjusted earnings before income taxes | 252,882 |  |  | 25,495 |  |  | 269,312 |  |  | 25,512 |  |  | (42,063) |  |  | (25,374) |
Interest expense | 25,973 |  |  |  |  |  |  |  |  |  |  | 25,973 |
Interest income | (599) |  |  |  |  |  |  |  |  |  |  | (599) |
Adjusted earnings before net interest and taxes (Adjusted EBIT) | 278,256 |  |  | 25,495 |  |  | 269,312 |  |  | 25,512 |  |  | (42,063) |  |  | — |
Depreciation and amortization | 162,414 |  |  | 70,159 |  |  | 56,232 |  |  | 28,031 |  |  | 7,992 |  |  |
Purchase accounting adjustments included in Depreciation and amortization above | (3,367) |  |  | (2,700) |  |  | (667) |  |  |  |  |  |  |
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | $ | 437,303 |  |  | $ | 92,954 |  |  | $ | 324,877 |  |  | $ | 53,543 |  |  | $ | (34,071) |  |  | $ | — |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | 20.1 | % |  | 9.7 | % |  | 35.5 | % |  | 17.6 | % |  | ​ |  | ​

43

Table of Contents

​ | Nine Months Ended
​ | September 30, 2019
​ | ​ |
​ | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | $ | 2,188,399 |  |  | $ | 1,037,921 |  |  | $ | 823,891 |  |  | $ | 326,587 |  |  | $ | — |  |  | $ | — |
​ |  |  |  |  |  |  |  |  |  |  |
Reported net income | $ | 193,689 |  |  |  |  |  |  |  |  |  |  |
Reported income taxes | 80,684 |  |  |  |  |  |  |  |  |  |  |
Reported income before income taxes | 274,373 |  |  | 66,407 |  |  | 244,101 |  |  | 29,234 |  |  | (42,239) |  |  | (23,130) |
Adjustments: |  |  |  |  |  |  |  |  |  |  |
Restructuring initiatives | 17,286 |  |  | 14,869 |  |  | 381 |  |  | 826 |  |  | 1,210 |  |  |
Transaction costs related to acquisitions | 1,767 |  |  | 34 |  |  | 1,579 |  |  | 154 |  |  |  |  |
Purchase accounting adjustments related to acquisitions and investments | 869 |  |  |  |  | 869 |  |  |  |  |  |  |
Adjusted earnings before income taxes | 294,295 |  |  | 81,310 |  |  | 246,930 |  |  | 30,214 |  |  | (41,029) |  |  | (23,130) |
Interest expense | 26,868 |  |  |  |  |  |  |  |  |  |  | 26,868 |
Interest income | (3,738) |  |  |  |  |  |  |  |  |  |  | (3,738) |
Adjusted earnings before net interest and taxes (Adjusted EBIT) | 317,425 |  |  | 81,310 |  |  | 246,930 |  |  | 30,214 |  |  | (41,029) |  |  | — |
Depreciation and amortization | 144,574 |  |  | 62,101 |  |  | 48,623 |  |  | 26,149 |  |  | 7,701 |  |  |
Purchase accounting adjustments included in Depreciation and amortization above | (869) |  |  |  |  | (869) |  |  |  |  |  |  |
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | $ | 461,130 |  |  | $ | 143,411 |  |  | $ | 294,684 |  |  | $ | 56,363 |  |  | $ | (33,328) |  |  | $ | — |
​ | ​ |  | ​ |  | ​ |  | ​ |  | ​ |  | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | 21.1 | % |  | 13.8 | % |  | 35.8 | % |  | 17.3 | % |  | ​ |  | ​

​

Net Debt to Net Capital Reconciliation | September 30, |  | December 31,
​ | 2020 |  | 2019
​ | ​ |  | ​
Notes payable, revolving credit facility and overdrafts | $ | 95,200 |  |  | $ | 44,259 |
Current maturities of long-term obligations, net of unamortized debt issuance costs | 66,056 |  |  | 65,988 |
Long-Term Obligations, net of unamortized debt issuance costs | 1,039,935 |  |  | 1,085,453 |
Total Debt | 1,201,191 |  |  | 1,195,700 |
Less: | ​ |  | ​
Cash and equivalents | 226,546 |  |  | 241,970 |
Net Debt | $ | 974,645 |  |  | $ | 953,730 |
​ | ​ |  | ​
Total Stockholders' Equity | $ | 1,759,955 |  |  | $ | 1,572,252 |
Net Debt | 974,645 |  |  | 953,730 |
Net Capital | $ | 2,734,600 |  |  | $ | 2,525,982 |
​ | ​ |  | ​
Net Debt to Net Capital | 35.6 | % |  | 37.8 | %

44

Table of Contents
​

Free Cash Flow Reconciliation | September 30, |  | September 30,
​ | 2020 |  | 2019
​ | ​ |  | ​
Net Cash Provided by Operations | $ | 381,427 |  |  | $ | 380,381 |
​ | ​ |  | ​
Less: | ​ |  | ​
Capital Expenditures | 173,365 |  |  | 186,841 |
Free Cash Flow | $ | 208,062 |  |  | $ | 193,540 |

​
FOREIGN CURRENCY
Because of our international presence, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc and other Asian, European and South American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. We manage our exposures to foreign exchange principally with forward exchange contracts to economically hedge recorded transactions and firm purchase and sales commitments denominated in foreign currencies. Changes in exchange rates on such inter-country sales could materially impact our results of operations. During the third quarter of 2020, the U.S. dollar weakened compared to the major European currencies while it appreciated against most Latin America and Asian currencies. This resulted in an additive impact on our translated results during the third quarter of 2020 when compared to the third quarter of 2019.
Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries pursuant to U.S. GAAP. We have changed the functional currency from the Argentinian peso to the U.S. dollar. We remeasure our peso denominated assets and liabilities using the official rate. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result of these currency controls, a legal mechanism known as the Blue Chip Swap emerged in Argentina for reporting entities to transfer U.S. dollars. The Blue Chip Swap rate has diverged significantly from Argentina’s “official rate” due to the economic environment. During the second quarter of 2020, we transferred U.S. dollars into Argentina through the Blue Chip Swap method and we recognized a gain of $1.0 million. This gain helped to offset foreign currency losses due to our Argentinian peso exposure and devaluation against the U.S. dollar. For the nine months ended September 30, 2020, our Argentinian operations contributed less than 2.0% of consolidated net assets and revenues.
QUARTERLY TRENDS
Our results of operations in the last quarter of the year typically are negatively impacted by customer plant shutdowns in December. In addition to the significant impact of COVID-19 on our business, our results of operations in a quarterly period could be impacted by factors such as the seasonality of certain products within our segments, changes in foreign currency rates, changes in product mix, changes in material costs, changes in growth rates in the markets to which our products are sold and changes in general economic conditions in any of the countries in which we do business.
LIQUIDITY AND CAPITAL RESOURCES
Given the diversification of our segments, we believe we are in a strong financial position and have the financial resources to meet our business requirements in the foreseeable future. Our primary uses of liquidity are to invest in equipment and facilities that are necessary to support our growth and to make acquisitions that will contribute to the achievement of our strategic objectives. Amid the COVID-19 pandemic, we are focused on preserving our liquidity and therefore we have temporarily suspended repurchasing shares of our common stock and discretionary contributions to our defined benefit plans. However, we intend to continue to pay quarterly dividends to our stockholders, invest in our business and make acquisitions as we consider necessary to achieve our strategic objectives. In the event that customer demand decreases significantly for a prolonged period of time due to the COVID-19 pandemic and adversely impacts our cash flows from operations, we would have the ability to restrict and significantly reduce capital expenditure levels as well as evaluate our acquisition strategy. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.
Cash and equivalents and restricted cash decreased to $231.4 million at September 30, 2020 from $247.0 million at December 31, 2019. Total short and long-term interest bearing debt of $1.2 billion at September 30, 2020 was unchanged from $1.2 billion at December 31, 2019. The ratio of our Net Debt (interest bearing debt less cash and equivalents) to Net Capital (stockholders’ equity plus Net Debt) decreased to 35.6% at September 30, 2020 compared to 37.8% at December 31, 2019. See the reconciliation under "Non-U.S. GAAP Measures".
45

Table of Contents
In the first nine months of 2020, our operations provided approximately $381.4 million in net cash flow compared to $380.4 million for the same period a year ago. In both periods, cash flow from operations was primarily derived from earnings before depreciation and amortization. The increase in cash provided by operations during the first nine months of 2020 is primarily attributable to better working capital management which offset lower net income.
We used $377.9 million in cash for investing activities during the first nine months of 2020 compared to $224.0 million during the same period a year ago. During the first nine months of 2020, $162.7 million of cash was utilized to fund the Fusion Acquisition. We invested $32.0 million in our 49% equity interest of BTY and $5.0 million in our 30% equity interest of Sonmol, which are accounted for as equity method investments. Additionally, we released $1.0 million relating to the working capital escrow settlement and paid an additional $463 thousand as a working capital payment related to our acquisition of Noble. Our investment in capital projects decreased $13.5 million during the first nine months of 2020 compared to the first nine months of 2019 due to timing of our capital expenditures. Our 2020 estimated cash outlays for capital expenditures are expected to be in the range of approximately $240 to $250 million but could vary due to changes in exchange rates as well as the timing of capital projects.
Financing activities used $26.7 million in cash during the first nine months of 2020 compared to $146.2 million in cash used by financing activities during the same period a year ago. During the first nine months of 2020, we received net proceeds from our U.S. group credit facility of $70.0 million and stock option exercises of $51.1 million. We used cash on hand to pay $69.4 million of dividends, net repayments of $14.0 million related to our notes payable and overdrafts and $61.7 million related to our outstanding long-term debt obligations.
We hold U.S. dollar and euro-denominated debt to align our capital structure with our earnings base. We also maintain a multi-currency revolving credit facility with two tranches, providing for unsecured financing of up to $300 million that is available in the U.S. and up to €150 million that is available to our wholly-owned UK subsidiary. Each borrowing under the credit facility will bear interest at rates based on LIBOR, prime rates or other similar rates, in each case plus an applicable margin. A facility fee on the total amount of the facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. $95.0 million was utilized under our U.S. facility and no balance was utilized under our euro-based revolving credit facility as of September 30, 2020. The $25.0 million balance at December 31, 2019 under our U.S. credit facility was repaid during the first quarter of 2020. Credit facility balances are included in notes payable, including revolving credit facilities on the Condensed Consolidated Balance Sheets.
​
Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

​ | Requirement |  | Level at September 30, 2020
Consolidated Leverage Ratio (1) | Maximum of 3.50 to 1.00 |  | 1.81 to 1.00
Consolidated Interest Coverage Ratio (1) | Minimum of 3.00 to 1.00 |  | 15.92 to 1.00

__________________________________________________________
(1)Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.
​
Based upon the above consolidated leverage ratio covenant, we have the ability to borrow approximately an additional $938.1 million before the 3.50 to 1.00 maximum ratio requirement is exceeded.
Our foreign operations have historically met cash requirements with the use of internally generated cash or uncommitted short-term borrowings. We also have committed financing arrangements in both the U.S. and UK as detailed above. We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances.
On October 15, 2020, the Board of Directors declared a quarterly cash dividend of $0.36 per share payable on November 18, 2020 to stockholders of record as of October 28, 2020.
CONTINGENCIES
The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. Please refer to Note 12 - Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements for a discussion of contingencies affecting our business.
46

Table of Contents
OFF-BALANCE SHEET ARRANGEMENTS
We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating leases. Most of the operating leases contain renewal options and certain equipment leases include options to purchase during or at the end of the lease term. As a result of the adoption of ASU 2016-02 and subsequent amendments, which requires organizations to recognize leases on the balance sheet, we do not have significant off-balance sheet arrangements. Please refer to Note 7 – Leases of the Notes to Condensed Consolidated Financial Statements.
RECENTLY ISSUED ACCOUNTING STANDARDS
We have reviewed the recently issued accounting standards updates to the FASB’s Accounting Standards Codification that have future effective dates. Standards that have been adopted during 2020 are discussed in Note 1 – Summary of Significant Accounting Policies of the Notes to Condensed Consolidated Financial Statements.
In March 2020, the FASB issued ASU 2020-04, which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments to this update apply only to contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. The new standard is effective upon issuance and can be adopted any time prior to December 31, 2022. We do not anticipate that this new guidance will have a significant impact on our consolidated financial statements.
In August 2018, the FASB issued ASU 2018-14, which amends disclosure requirements for defined benefit pension and other postretirement plans. The amendments in this update remove disclosures that are no longer considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. The new standard is effective for fiscal years ending after December 15, 2020. As this update only modifies disclosure requirements, we do not expect that this guidance will have a significant impact on our consolidated financial statements.
Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.
OUTLOOK
We expect the company to continue to achieve core growth. Rising demand in many end markets is expected to more than offset COVID-19 related declines in some of our end markets. We are proud of the way our employees have responded to the difficult year and we are performing well. We expect our Pharma business to continue to do well with existing business and increased opportunities directly and indirectly related to the pandemic.
We expect earnings per share for the fourth quarter of 2020, excluding any restructuring expenses and acquisition-related costs, to be in the range of $0.84 to $0.92 and this guidance is based on an effective tax rate range of 27% to 29%.
FORWARD-LOOKING STATEMENTS
Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Significant Developments, Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, Contingencies and Outlook sections of this Form 10-Q. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to:
•outbreaks of pandemics, including the impact of COVID-19 on our global supply chain and our global customers and operations, which has elevated and may or will continue to elevate many of the risks and uncertainties discussed below;
•economic conditions worldwide, including potential deflationary or inflationary conditions in regions we rely on for growth;
•political conditions worldwide, including the impact of the UK leaving the European Union (Brexit) on our UK operations;
•significant fluctuations in foreign currency exchange rates or our effective tax rate;
•the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate;
•financial conditions of customers and suppliers;
•consolidations within our customer or supplier bases;
•changes in customer and/or consumer spending levels;
•loss of one or more key accounts;
•the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers;
47

Table of Contents
•fluctuations in the cost of materials, components and other input costs (particularly resin, metal, anodization costs and transportation and energy costs);
•our ability to successfully implement facility expansions and new facility projects;
•our ability to offset inflationary impacts with cost containment, productivity initiatives or price increases;
•changes in capital availability or cost, including interest rate fluctuations;
•volatility of global credit markets;
•our ability to identify potential new acquisitions and to successfully acquire and integrate such operations and products, including the successful integration of the businesses we have acquired, including contingent consideration valuation;
•direct or indirect consequences of acts of war, terrorism or social unrest;
•cybersecurity threats that could impact our networks and reporting systems;
•the impact of natural disasters and other weather-related occurrences;
•fiscal and monetary policies and other regulations;
•changes or difficulties in complying with government regulation;
•changing regulations or market conditions regarding environmental sustainability;
•work stoppages due to labor disputes;
•competition, including technological advances;
•our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;
•the outcome of any legal proceeding that has been or may be instituted against us and others;
•our ability to meet future cash flow estimates to support our goodwill impairment testing;
•the demand for existing and new products;
•the success of our customers’ products, particularly in the pharmaceutical industry;
•our ability to manage worldwide customer launches of complex technical products, particularly in developing markets;
•difficulties in product development and uncertainties related to the timing or outcome of product development;
•significant product liability claims;
•the execution of our business transformation plan; and
•other risks associated with our operations.
​
Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Please refer to Item 1A (Risk Factors) of Part I included in our Annual Report on Form 10-K for the year ended December 31, 2019 and to Item 1A (Risk Factors) of Part II of this report for additional risk factors affecting the Company.
48

Table of Contents
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our entities. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso and Swiss franc, among other Asian, European, and South American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar relative to foreign currencies has an additive translation effect on our financial condition and results of operations.
Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.
We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain firm purchase and sales commitments and intercompany cash transactions denominated in foreign currencies.
The table below provides information as of September 30, 2020 about our forward currency exchange contracts. The majority of the contracts expire before the end of the fourth quarter of 2020.

Buy/Sell | Contract Amount (in thousands) |  | Average Contractual Exchange Rate |  | Min / Max Notional Volumes
​ | ​ |  | ​ |  | ​
EUR / USD | $ | 13,585 |  |  | 1.1671 |  |  | 13,114-24,247
EUR / BRL | 9,300 |  |  | 6.3817 |  |  | 9,300-10,173
CZK / EUR | 4,998 |  |  | 0.0377 |  |  | 3,408-5,029
EUR / INR | 3,864 |  |  | 88.6650 |  |  | 3,806-3,898
EUR/THB | 3,478 |  |  | 37.0688 |  |  | 1,276-3,478
MXN / USD | 2,400 |  |  | 0.0432 |  |  | 2,400-2,610
CHF / EUR | 2,374 |  |  | 0.6405 |  |  | 2,374-2,874
EUR/CNY | 1,174 |  |  | 8.2267 |  |  | 0-3,569
EUR / MXN | 1,062 |  |  | 26.5924 |  |  | 1,062-2,165
GBP / EUR | 733 |  |  | 1.1022 |  |  | 733-889
USD / EUR | 146 |  |  | 0.8494 |  |  | 146-8,297
EUR/CZK | 69 |  |  | 26.6496 |  |  | 0-69
Total | $ | 43,183 |  |  | ​ |  | ​

​
As of September 30, 2020, we have recorded the fair value of foreign currency forward exchange contracts of $0.1 million in prepaid and other and $0.4 million in accounts payable, accrued and other liabilities on the balance sheet. We also entered into a EUR/USD floating-to-fixed cross currency swap on July 20, 2017 to effectively hedge the foreign exchange and interest rate exposure on the $280 million bank term loan drawn by our wholly-owned UK subsidiary. The fair value of this cash flow hedge is $3.2 million reported in accounts payable, accrued and other liabilities on the balance sheet.
ITEM 4. CONTROLS AND PROCEDURES
DISCLOSURE CONTROLS AND PROCEDURES
Management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of our disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Exchange Act) as of September 30, 2020. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
During the fiscal quarter ended September 30, 2020, we implemented enterprise resource planning (“ERP”) systems at one operating facility. Consequently, the control environments have been modified at this location to incorporate the controls contained within the new ERP systems. Except for the foregoing, no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) occurred during our fiscal quarter ended September 30, 2020 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Amid the COVID-19 pandemic, we have implemented remote work arrangements and restricted non-essential business travel. These arrangements have not materially affected our ability to maintain our business operations, including the operation of financial reporting systems, internal control over financial reporting and disclosure controls and procedures.
49

Table of Contents
PART II - OTHER INFORMATION
ITEM 1A. RISK FACTORS
The following risk factor is in addition to the risks described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under Item 1A, “Risk Factors” filed with the SEC pursuant to the Exchange Act. The effects of the events and circumstances described in the following risk factors have elevated and may or will continue to elevate many of the risks contained in the Company’s Form 10-K, including the risks relating to a deterioration in economic conditions in a particular region or market, our fixed costs structure, reliance on single sourced materials and manufacturing sites and potential asset impairments.
The COVID-19 pandemic continues to adversely affect our business. Additional factors could exacerbate such negative consequences and/or create materially adverse effects. The COVID-19 pandemic adversely affected our sales of products to our travel and retail beauty business and on-the-go beverage customers in the nine months ended September 30, 2020 and that adverse impact may continue into the fourth quarter. Beginning in the first quarter of 2020, economic and health conditions in the United States and across most of the globe have changed rapidly. Customer demand across all segments, particularly our Beauty + Home and Food + Beverage segments, may decrease further from historical levels depending on the duration and severity of the COVID-19 pandemic and the extent of further resurgences, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages due to disruptions to our supply chain and distribution channels, delivery delays, increased risk associated with customer payments and reduced sales and operations, any of which could materially affect our stock price, business prospects, financial condition, results of operations and liquidity.
The ability of our employees to work may be significantly impacted by COVID-19. The majority of our office and management personnel are working remotely and the majority of our facilities remained operational during the first nine months of 2020 as each of our segments produce dispensing systems that have been determined to be essential products by various government agencies around the world. The health and safety of our workforce is of primary concern and we may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the virus. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources across the entire company, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, our ability to manage our business may be impaired, and operational risks, cybersecurity risks and other risks facing us even prior to the pandemic may be elevated.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
​
RECENT SALES OF UNREGISTERED SECURITIES
Certain French employees are eligible to participate in the FCP Aptar Savings Plan (the “Plan”). An independent agent purchases shares of common stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of common stock under the Plan. The agent under the Plan is Banque Nationale de Paris Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended September 30, 2020, the Plan purchased 316 shares of our common stock on behalf of the participants at an average price of $118.66, for an aggregate amount of $37 thousand. The Plan sold 6,123 shares of our common stock on behalf of the participants at an average price of $118.01, for an aggregate amount of $723 thousand during the same period. At September 30, 2020, the Plan owned 90,976 shares of our common stock.
ISSUER PURCHASES OF EQUITY SECURITIES
On April 18, 2019, we announced a share purchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.
During the three and nine months ended September 30, 2020, we did not repurchase any shares. As of September 30, 2020, there was $278.5 million of authorized share repurchases available to us. Amid the COVID-19 pandemic, we are focused on preserving our liquidity and therefore we have temporarily suspended repurchasing shares of our common stock.
50

Table of Contents
ITEM 6. EXHIBITS
​

Exhibit 10.1 |  | Amendment No. 2 to the Employment Agreement dated March 30, 2011, and amended February 10, 2016, of Gael Touya.
Exhibit 31.1 | ​ | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 31.2 | ​ | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 32.1 | ​ | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 32.2 | ​ | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 101 | ​ | The following information from our Quarterly Report on Form 10-Q for the third quarter of fiscal 2020, filed with the SEC on October 30, 2020, formatted in Inline Extensible Business Reporting Language (XBRL): (i) the Cover Page, (ii) the Condensed Consolidated Statements of Income – Three and Nine Months Ended September 30, 2020 and 2019, (iii) the Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2020 and 2019, (iv) the Condensed Consolidated Balance Sheets – September 30, 2020 and December 31, 2019, (v) the Condensed Consolidated Statements of Changes in Equity – Three and Nine Months Ended September 30, 2020 and 2019, (vi) the Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2020 and 2019 and (vii) the Notes to Condensed Consolidated Financial Statements. ​
Exhibit 104 | ​ | Cover Page Interactive Data File (embedded within the Inline XBRL document).

​
​
​
51

Table of Contents
SIGNATURE
​
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
​

​ | ​ | AptarGroup, Inc.
​ | ​ | (Registrant)
​ | ​ | ​
​ | By | /s/ ROBERT W. KUHN
​ | ​ | Robert W. Kuhn
​ | ​ | Executive Vice President,
​ | ​ | Chief Financial Officer and Secretary
​ | ​ | (Duly Authorized Officer and
​ | ​ | Principal Accounting and Financial Officer)
​ | ​ | ​
​ | ​ | ​
​ | ​ | Date: October 30, 2020

52